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SUMMARY.
The involvement of antibody-mediated, complement- 
dependent cell lysis in myasthenia gravis was 
investigated in vitro by using two sources of human- 
derived cell.
Lysis of human muscle cells in culture, was assayed 
by following the release of tritium-labelled carnitine 
selectively taken up by these cells. In the presence of 
exogenous complement, heat-inactivated serum from 5 
myasthenic patients, showed greater myotoxicity than 
did normal human serum, indicating the involvement of a 
complement-mediated effect in MG. More rigorous 
investigation of this system was hindered by problems 
arising from the sporadic supply of uncontaminated 
human muscle and an alternative source of human cells 
was sought.
A pharmacological profile of TE671 cells, using 
[12 5 1 ] a-BGT and other cholinergic ligands, established 
the cell line to be a carrier of a "muscle-type" AChR. 
The cells were accordingly used in cytotoxicity studies 
of complement-mediated lysis.
An assay involving release of intracellular lactate 
dehydrogenase (LDH) was initially examined, but despite 
many refinements, consistently higher lysis by 
myasthenic serum, compared with controls, could not be 
demonstrated. An alternative assay, depending on the 
release of [51Cr] from the cells gave similar results
leading to the eventual conclusion that TE671 cells, 
while readily lysed by hypotonic shock or detergent were 
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1INTRODUCTION.
Myasthenia gravis (MG) was first described in 1672 
by Dr. Thomas Willis. Since then, and especially in the 
last 25 years, a great deal of information concerning 
the disease has been recorded (for reviews, see Vincent, 
1980; Harrison and Behan, 1986). Clinically, MG is 
characterised by weakness and fatiguability of skeletal 
muscle, with a tendency to be made worse by activity.
It is now accepted that MG is an autoimmune disease 
and the nicotinic acetylcholine receptor (AChR) at the 
neuromuscular junction has been demonstrated to be the 
major autoantigen. Elevated levels of anti-(AChR) 
antibodies are found in the serum of about 90% of 
patients with the disease, which results in a loss of 
functional AChR and impairment of neuromuscular 
transmission. Understanding of the pathogenesis of MG is 
coupled to increasing knowledge of synaptic organisation 
and to structure and function of the AChR. In the 
generation of this knowledge, tissue culture systems and 
cell lines have proved valuable tools.
1.1 Neuromuscular transmission.
In the majority of mammalian muscles, each muscle 
fibre has a single region of contact with the axon of
2its controlling motor neurone. This region constitutes 
the neuromuscular junction (Fig. 1). Its function is to 
transfer the propagated nerve impulse from the motor 
nerve ending to the muscle fibre, resulting ultimately 
in muscular contraction. Although the nerve terminal 
and the post-synaptic membrane lie close together they 
are separated by a gap that must be bridged by 
acetylcholine in order to generate an action potential 
in the muscle fibre.
The sequence of events which results in muscular 
contraction may be summarised as follows:-
An action potential is propagated along the membrane 
of the motor neurone and invades the nerve terminal. 
Depolarisation of the terminal causes the release of 
quanta of acetylcholine. Each quantum contains 
approximately 10® molecules and is thought to be the 
contents of one synaptic vesicle. The vesicles are 
concentrated in the motor nerve terminal close to the 
post-synaptic membrane. The liberated acetylcholine 
rapidly diffuses across the synaptic cleft and binds to 
receptors on the crests of the folded post-synaptic 
muscle membrane. The binding of acetylcholine to the 
AChR in the post-synaptic membrane promotes a 
conformational change, associated with a brief (1 
millisecond) opening of an ion channel. This allows the 
passage of sodium and potassium ions down their 
electrochemical gradients. There is a net influx of 
sodium ions, resulting in a reduction of membrane 
potential or depolarisation of the muscle membrane,
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producing an "end-plate potential" (epp). If the 
summation of epps causes depolarisation to the threshold 
value, the muscle membrane generates an action potential 
which ultimately activates the contractile processes of 
the muscle fibre.
Normally, the amount of acetylcholine released and 
the number of AChRs activated is much larger than the 
minimum required to initiate muscular contraction. This 
provides a large safety factor, ensuring effective 
neuromuscular transmission. In the absence of a nerve 
impulse, spontaneous release of a small amount of 
acetylcholine from the nerve ending occurs, generating 
small depolarisations - miniature end-plate potentials 
(mepps). These potentials are not large enough by 
themselves to produce muscle action potentials, and are 
thought to be the result of the random bursting of 
single vesicles.
The action of acetylcholine is terminated by its 
dissociation from the AChR, subsequent reassociation is 
minimised by acetylcholinesterase activity.
1.2 Molecular characterisation of AChR.
Since the early 1900*s, two classes of AChR, 
muscarinic and nicotinic, have been recognised; the 
classes are based on the differential effects of the 
alkaloids muscarine and nicotine (Dale, 1914; Dixon, 
1907). While both muscarinic and nicotinic receptors
5have a common neurotransmitter in acetylcholine, that 
is where the similarity ends.
The state of knowledge of the nicotinic AChR is 
more advanced than for any other type of receptor. Much 
of the progress in generating knowledge about this 
"archetypal" receptor protein can be attributed to four 
factors:-
i) The discovery of an abundant source of AChR in 
the elasroobranch and teleost fishes (Torpedo and 
Electrophorus sp.).
ii) The use of snake a-neurotoxins, principally a- 
bungarotoxin (a-BGT), as specific, high affinity probes 
for the AChR at the neuromuscular junction.
iii) The ability of detergents to solubilise the 
protein from its membrane environment without loss of 
biological activity.
iv) The more recent application of the 
sophisticated and powerful techniques of molecular 
biology, including the translation system of the Xenopus 
oocyte•
1.2.1. Source of AChR:-
1.2.1.1. Torpedo as a model.
The majority of information concerning the AChR has 
come from studies on Torpedo electric organ, this work 
has proceeded to include mammalian AChR. Details
6pertaining to the mammalian AChR will be included where 
appropriate.
There are similarities between the AChR in the 
neuromuscular junction and those in the electric organs 
of Torpedo and Electrophorus. In Torpedo the embryonic 
fish contains muscle-like precursor cells that develop 
into the orientated stack of polar cells comprising the 
electric organs. These contain cells, electrocytes, that 
are the counterparts of muscle cells, but lack the 
contractile elements. On only one side of the 
electrocyte is the plasmalemma endowed with AChRs but 
the density is high (in Torpedo 25% of the total 
membrane protein). In contrast, in normal adult 
innervated muscle the AChR comprises less than 1% of the 
total membrane protein. AChRs from Torpedo are related 
by structure, function and evolution to those of the 
neuromuscular junction in vertebrates. The electric 
organ is, therefore, a rich and homogeneous source which 
has been used extensively for biochemical 
characterisations (for reviews, see Karlin, 1980; Conti- 
Tronconi and Raftery, 1982; Popot and Changeux, 1984; 
McCarthy et al., 1986; Hucho, 1986). However, after
denervation of vertebrate muscle, the number of AChRs 
increases up to 50-fold, providing a useful and enriched 
source of receptors which has facilitated their 
purification and chacterisation (for review, see Dolly 
and Barnard, 1984).
71.2 .1. 2 . Snake a-neurotoxins.
The neurotoxins were first purified by Chang and 
Lee (1962) who demonstrated that they produce an anti- 
depolarising block of the AChR at the neuromuscular 
juction, in a manner similar to that of d-tubocurarine, 
a cholinergic antagonist (Lee, 1972). Although their 
structure is very different from those of acetylcholine 
analogues (Fig. 2), the a-neurotoxins bind non- 
covalently but with high affinity (Kd 10-11M) and 
specificity, at or near the acetylcholine binding site 
(Section I.2.4.4.).
Their usefulness as probes has relied on the 
finding that they can be labelled with radioactive, 
fluorescent or enzyme markers. a-BGT from Bungarus 
multicinctus is normally used because of the near 
irreversibility of its binding to AChR (Lee,1972) and 
the ease with which it can be labelled without loss of 
biological activity. a-BGT can be radioiodinated with 
[12 51 ] to high levels of specific radioactivity, and 
subsequently separated from the unlabelled toxin 
(Section 2.1.). Fluorescent derivatives of a-BGT, 
prepared by reaction with tetramethyl-rhodamine 
isothiocyanate, are generally used for studies on 
muscle, but fluorescein conjugates have also been used 
successfully. Finally, physiologically active conjugates 
of a-BGT and peroxidase can be made or, alternatively 
anti-(a-BGT) antibodies can be used in conjunction with 
a labelled second antibody (Barnard, 1979). The latter
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9techniques allow the AChR to be localised by using both 
light and electron microscopy (Barnard, 1979).
1.2.2. Protein chemistry.
1.2.2.1. Isolation and purification of AChR.
The AChR is an integral membrane protein that can 
be extracted with non-ionic detergent (eg: Triton X- 
100). In solution as detergent micelles it is still 
capable of binding a-toxins and cholinergic ligands. 
Further purification is now usually effected by using 
the less avid a-toxin from Naja naja siamensis and 
elution with cholinergic ligands. Purified AChR is freed 
from eluting agents by standard techniques such as 
dialysis or ion-exchange chromatography.
Purification of mammalian AChR proved more 
difficult than for the electroplaque AChR, mainly 
because of the much lower content of AChR in the muscle 
membrane (2500-fold less than its piscine counterpart, 
Dolly and Barnard, 1984) and the high level of 
proteolysis that occurs during purification (for 
reviews, see Dolly, 1979; Dolly and Barnard, 1984).
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1.2.3* Properties of the isolated AChR.
1.2.3.1. Molecular weight.
The subunit composition of the purified Torpedo 
AChR has been determined by denaturation with sodium 
dodecyl sulphate (SDS) followed by polyacrylamide gel 
electrophoreris (PAGE). It is now generally agreed that 
the electric organ AChRs are comprised of four subunits, 
a, 3, t and 6 with apparent molecular weights of 
approximately 40000, 49500, 57000 and 64000 Daltons in 
the stoichiometric ratio 2:1:1:1.
1.2.3 . 2 . Reconstitution of AChR in model membranes.
Re-assembly of the detergent-solubilised, purified 
receptor into a membrane environment constitutes proof 
that the purified protein contains all the elements of a 
functional AChR. The AChR has now been reconstituted 
into lipid bilayer vesicles and lipid films with 
complete recovery of ligand binding and ion- 
permeability properties (Anholt, 1981; McNamee and 
Ochoa, 1982).
1.2.3 . 3 . Molecular shape.
Most studies concerning the shape of the AChR 
molecule were carried out using Torpedo AChR. Since the 
AChR molecule, formed by the four subunits mentioned
11
above, contains both the binding sites for the 
cholinergic ligands and the cation gating system (for 
review, see Conti-Tronconi and Raftery, 1982), it should 
span the post synaptic membrane, A direct demonstration 
that the AChR molecule protrudes from both sides of the 
post synaptic membrane was obtained after treatment with 
proteolytic enzymes and subsequent utilisation of anti- 
(AChR) antibodies binding to post synaptic membrane 
fragments of Torpedo (Tarrab-Hazdai et al. , 1978). Both 
the outside and inside surfaces were labelled by 
antibodies, thus demonstrating that the AChR is a
transmembrane protein complex.
1.2.3.4. Electron microscopy.
The five membrane-spanning subunits of the AChR 
have been resolved in electron microscope images 
(Brisson and Unwin, 1985) and are shown to lie at
pentagonally symmetrical positions in a ring-like 
structure (8nm diameter), around a densely stained 
central pit (2.5nm diameter), the presumed ion-channel 
(Hucho, 1986). The channel consists of a wide synaptic 
portion and a narrow portion extending through the
membrane into the interior of the cell (Fig. 3).
12
Fig. 3.
a) A 3D electron image map of receptor molecules in 
crystals grown from native Torpedo membrane vesicles 
viewed as they would appear from the synaptic cleft. The 
receptor is composed of a pentagonally symmetrical array 
of 5 subunits of similar size, lying perpendicular to 
the membrane plane. Thus, all five subunits are equally 
spaced around a pore, thought to be the ion channel and 
are orientated in a similar fashion in the cell 
membrane.
b) Side view (through the channel axis) with the 
central plane of the bilayer shown by a broken line. In 
this section, it can be seen that the receptor is a 
cylindrical molecule of almost constant diameter, the 
ion channel opening is wide at the synaptic end of the 
molecule and has an unresolved part extending through 
the membrane into the cytoplasm.







1.2 .4 .1. Cloning and sequencing AChR subunits: 
homologous polypeptides.
A prerequisite for understanding the molecular 
basis of the normal functions of the AChR was the 
elucidation of the primary structures of the constituent 
polypeptides of the receptor. One of the first 
descriptions of the amino acid compositions of the AChR 
came after Raftery et al•, (1980) chemically sequenced 
the N-terminal 54-56 amino acids of the amino termini of 
the four polypeptides of T. californica and noticed 
considerable homology between subunits. Subsequently, 
Numa and his many co-workers (Noda et al.f 1982) using 
the powerful recombinant DNA techniques, identified the 
mRNA for the a-subunit and cloned and sequenced the 
cDNA.
The same techniques allowed determination of the 
sequences of the 3 and 6 subunit precursors and 
subsequently of the polypeptide chains for all four 
Torpedo subunits (Noda et al., 1983a, b; Claudio et a l ., 
1983).
The application of recombinant DNA technology has 
also been used for further structural and functional 
analysis of mammalian AChR. Sequences of polypeptide 
chains for calf and human AChR subunits have been 
determined (Noda et al^ . , 1983c ; Tanabe et al. , 1984;
Takai et a l ., 1984; Kubo et a l ., 1985; Shibihara et
15
a l ., 1985). Comparison of these subunits revealed
extensive homologies throughout their lengths and also 
between species; there is about 80% homology between a- 
subunits of Torpedo and human muscle and about 55% 
homology of the other subunits between these species 
(Noda et a l . , 1983c; Takai et a_l. , 1984; Tanabe et a l . , 
1984: Kubo et al•, 1985).
These homologies confirmed the earlier suggestion 
(Raftery et a_l. , 1980) that the genes for the four
polypeptide chains may be derived from a common 
ancestor. It has further been suggested that a/3 
diverged from t/6, and that the a-subunit subsequently 
diverged again later from 3, t and 6 (Anderson, 1987).
In addition to the four subunits described above, a 
novel subunit, termed the € subunit, has been discovered 
by cloning and sequencing calf muscle cDNA (Takai et 
a l ., 1985). This subunit shows greatest homology with 
the x subunit and functional expression studies (see 
section 1.2.4.2. below) suggest that it replaces the t 
subunit in adult muscle AChR.
1.2.4.2 . Functional expression.
Expression of the subunit raRNA's into the Xenopus 
oocyte, showed that all four subunits are necessary for 
assembly and membrane insertion of a functional receptor 
(Mishina et al., 1985). Takai et aJU (1985) showed that
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the calf € subunit can substitute for calf x or Torpedo 
x subunits to create a functional AChR. The functional 
system can be used to investigate ligand binding, 
electrophysiological properties and the effects of 
substitutions or deletions of amino acids. Takai et a l . 
(1985) used this to advantage by demonstrating that 
substitution of 6 for x subunits resulted in altered 
ionic channel properties.
Mishina et a_l. (1986) suggested that different forms 
of the AChR occur in mammalian skeletal muscle during 
development. The AChR with the € subunit is present 
predominantly at the neuromuscular junction in adult 
muscle, whereas in fetal muscle and also in denervated 
muscle, AChRs with x subunits are found in the 
extrajunctional regions. These types of AChR differ in 
their channel properties and also in the number of 
acidic amino acid residues. Mishina et <rl. (1986) 
proposed that the developmental changes in the AChR 
channel properties are as a result of nerve-induced 
changes in AChR gene expression.
1.2.4.3. Models of AChR structure.
Comparison of the cDNA sequences for all four (a, 
&, x and 4) gene products of Torpedo have revealed the 
following features. Each sequence contains four very 
hydrophobic sequences which form a-helices long enough
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to form transmembrane domains (designated M1-M4) (Noda 
et al., 1983abc; Devillers-Thiery et al.f 1983; Tanabe 
et al., 1984; Takai et a l . , 1984; Kubo et al. , 1985;
Shibahara et al • , 1985), similar to those previously
described for bacteriorhodopsin (Ovchinnikov et al.,
1979). An additional sequence with alternating polar and 
hydrophobic amino acids has been recognised in all
subunits. It was suggested that this might form an 
amphipathic transmembrane helix with the charged face 
contributing the ion-channel lining (Finer-Moore and
Stroud, 1984). This suggestion has now been discredited 
(see below).
The use of monoclonal antibodies raised against 
whole subunits or parts of the AChR and the construction 
of synthetic peptides based on previously described 
sequences (see Lindstrom, 1986), have aided in the 
location of specific polypeptide sequences with respect 
to the membrane.
The precise transmembrane orientation of the AChR 
subunit polypeptide chains is uncertain, although
several models have been proposed (Guy, 1986) (Fig. 4). 
It is evident that each subunit has a large amino 
terminal region on the synaptic face. This contains the 
sites for glycosylation (Anderson and Blobel, 1981) and, 
in the a subunits, contains the high affinity agonist 
and antagonist binding sites (Kao et al,. , 1984. See also 
Section I.2.4.4.). Sites for phosphorylation have been 
demonstrated to be on the cytoplasmic side of the 
membrane (Huganir et a l ., 1984). Given that the N-
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Fig. 4. Primary sequence and possible transmembrane 
configurations of nicotinic receptor subunits.
a) Primary sequence typical of nicotinic receptor 
subunits, showing the relative positions of the residues 
(note that cys 192 and 193 are only found in the a 
subunits), hydrophobic spans capable of membrane 
insertion (designated Ml, M2, M3 and M 4 ) and the 
amphipathic helix (A). Dashed lines indicate regions of 
variable length and low sequence conservation between 
subunits. Amino acid numbering is based on the Torpedo a 
subunit sequence.
b) Model of the transmembrane configuration of an a 
subunit, showing the relative positions of the conserved 
amino acids and domains indicated in (a). This 
simplified model is derived (V.B. Cockcroft, 
unpublished) from available biochemical and
physicochemical data; the cytoplasmic and extracellular 
protrusions are consistent with the dimensions of the 
nicotinic receptor derived from electron imaging (see 
Fig. 3). The agonist binding site would face into the 
mouth of the receptor channel which is formed from 5 
subunits creating a cylindrical structure. Four membrane 
crossings per subunit and an extracellular C-terminus 
have previously been proposed by Noda et ad. (1982), 
Devil lers-Thiery et a_l. (1983) and Claudio et a l . 
(1983).
c) Alternative models propsed by 1. Guy (1984) and 
Finer-Moore and Stroud (1984), incorporating the 
amphipathic segment, A, as a membrane spaaning region, 
and 2. Ratnam et al. (1986).
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terminus is extracellular, the number of membrane 
crossings will determine whether the C-terminus is 
intracellular or extracellular. This, however remains in 
dispute•
The involvement of the amphipathic helix (A) in the 
formation of the putative ion-channel has been 
questioned. Recent evidence, based on photoaffinity 
labelling studies with non-competitive channel blockers 
(Giraudat et al., 1986; Hucho, 1986; Changeux and Revah, 
1987; Changeux et a^., 1987; Changeux et al., 1989)
suggests that serine 262 of the 6 subunit in M2 and its 
analogous residues in other subunits contributes to the 
ion-channel (Fig. 5a). It had previously been noticed 
(Guy, 1986) that the M2 region was the most highly 
conserved of all transmembrane regions. Expression 
studies involving chimeric 6 subunits (Imoto et a l .,
1986), site-directed mutagenesis of specific clusters of 
amino acids in the serine 262 region (Imoto et a l ., 
1988) and the construction of a synthetic peptide 
mimicking the sequence of the putative transmembrane M2 
segment in Torpedo that forms discrete ion-channels in 
membrane bilayers (Oiki et a l ., 1988), have confirmed 




a) Hypothetical organisation of the ion channel 
based upon chlorproroazine (CPZ) labelling data: the 
transmembrane hydrophobic helix M2 is assumed to line 
the ion channel•
b) Hypothetical organisation of the acetylcholine 
binding site inferred from [P(N,N)-dimethylaminobenzene 
diazonium fluoroborate] (DDF) labelling data: according 
to this scheme three loops from the large hydrophilic 
domain would contribute to this site.











1.2.4.4. Acetylcholine binding site.
The binding sites for acetylcholine have been 
located, one on each of the synaptic surfaces of the two 
a subunits (Kistler et ad., 1982; Kubalek et srl. , 1987). 
They can be labelled with a-BGT (Tzartos and Changeux, 
1984; Wilson et ad., 1984) or by the two major 
quarternary alkylating agents 4-(N-maleimido)-
benzyltrimethylaramonium (MBTA) (Weill et ad., 1974; 
Cahill and Schmidt, 1984) and bromacetylcholine (Damle 
et a l ., 1978; Lydiatt et al. , 1979). These affinity
ligands are potent inhibitors of acetylcholine binding 
and covalently label the site by interaction with a 
reducible disulphide bond in close proximity to the 
acetylcholine binding site.
On the basis of the primary sequence of the a 
subunit, four cysteine (cys) residues were found in the 
N-terrainal region at positions 128, 142, 192 and 193 
(Noda et al. , 1982; Devil lers-Thiery et a_l., 1983). It 
was concluded that a reducible disulphide bond existed 
between cys 128 and 142. Using the affinity labelling 
technique, Kao and Karlin (1984) demonstrated that MBTA 
labelled the adjacent cys residues at positions 192/193 
and not at 128 and 142. As homologues of cys 128 and 142 
occur in all subunits but cys 192/193 are unique to the 
a subunit (Noda et ad., 1983a; Claudio et al^ . , 1983), 
the functional roles of each of these cys residues in 
the a subunit was investigated by replacing each 
cysteine with serine by site directed mutagenesis
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(Mishina et ad., 1985). From their results, Mishina et 
a l . (1985) speculated that cys 192/193 of the a subunit 
have a specific role in agonist binding, whilst cys 128 
and 142 are essential for maintaining the proper 
conformation of the AChR molecule; they did not, 
however, rule out the possibility that these residues
might also be involved in agonist binding (see also Fig.
5b) .
1.2.5. Immunological profile of AChR.
Antibodies made in animals immunised with native 
AChRs are directed primarily at the extracellular
surface of the AChR (Froehner, 1981). Although 
antibodies are produced to many parts of the AChR, 60- 
70% are directed at one region found on the a subunits 
(Tzartos and Lindstrom, 1980; Tzartos et al., 
1981,1983). Monoclonal antibodies (mAbs) have been 
mapped on native receptor using competitive binding 
techniques (Tzartos and Lindstrom, 1980; Tzartos et al., 
1981). This approach showed that the majority of mAbs 
raised against an intact receptor were directed at the 
same particular region, termed the main immunogenic 
region (MIR). The binding sites for some of the mAbs 
could be estimated with some precision after the
elucidation of the primary sequence (see section
1.2.4.1.) and the MIR has been mapped to the general 
region between amino acids 46 and 127 on the a subunit
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(Ratnam et ad.f 1986; Barkas et ad., 1987; Kubalek et 
ad., 1987). The MIR is a well conserved feature of the 
AChR, but its function is unknown (Lindstrom et ad.,
(A
1988^) , although it is known to be important in the 
autoimmune disease myasthenia gravis.
1.2.6. Neuronal AChR.
In the central nervous system, there are nicotinic 
AChRs which belong to the same gene family as AChRs from 
muscle (for review, see Lindstrom et ad., 1987). These 
AChRs can, however, be distinguished from muscle AChRs 
by virtue of their pharmacological profile (for reviews, 
see Wonnacott, 1987; Colquhoun et al ., 1987).
AChRs found at the ganglia have yM affinity for 
nicotine, as do muscle AChRs (Kemp and Morley, 1986), 
whereas AChRs from brain have nM affinity for nicotine. 
Unlike muscle AChRs, the neuronal AChRs do not bind a- 
BGT (Lindstrom et ad., 1987).
In comparison with the muscle AChRs, neuronal AChRs 
have only two types of subunit, one is believed to be 
structural like the 3, t or 6 subunits from muscle 
AChRs, the other is acetylcholine binding, like the a 
subunits from muscle (Whiting and Lindstrom, 1987). In 
neurons, there are also a-BGT binding proteins of 
unknown function and uncertain composition. These are 
members of the AChR gene family but do not contain the 
AChR gated cation channels (Lindstrom et al., 1987).
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1.3. Myasthenia gravis.
The first evidence for the direct implication of the 
neuromuscular junction in MG came after Mary Walker 
(1934) noticed similarities in patients with MG and 
patients suffering from curare poisoning.
The elucidation of the precise site of the defect in 
MG was aided by electrophysiological studies. The 
muscles of MG patients have abnormally small end plate 
potentials (epps), which are either below the threshold 
required to initiate the contractile processes or 
rapidly become so during repetitive stimulation 
(Elmqvist et ad., 1964). Other studies revealed that in 
MG patients the action potential generated by the nerve 
was normal but that the miniature end plate potentials 
(mepps) were reduced (Elmqvist et a_l. , 1964; Santa et
a l ., 1972; Albuquerque et ad., 1976), while in vitro
studies showed that motor end-plates showed reduced 
sensitivity to iontophoretically applied acetylcholine 
(Rash et a l ., 1976). The number of acetylcholine
molecules per quantum (Cull-Candy et a l ., 1979) and the 
number of quanta per impulse (Elmqvist et a l .,1964; 
Lindstrom and Lambert, 1978; Cull-Candy et a l ., 1978,
1980) have now been shown to be normal at myasthenic 
nerve terminals, reinforcing the idea of a post synaptic 
defect. The question of the location of the primary 
lesion was, in fact, resolved following the availability
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of the post-synaptically acting snake neurotoxins 
(Section 1.3.2.). Using iodinated a-BGT, Farabrough et 
a l . (1973) demonstrated a reduction in the number of a-
BGT binding sites in myasthenic end-plates, indicating a 
reduced number of AChRs. It has been experimentally 
demonstrated that a reduction in the number of AChRs is 
sufficient to produce the characteristic features of MG.
Changes in the morphology at myasthenic end-plates 
suggest degeneration and regeneration of the 
neuromuscular junction with flattening and
simplification of the post synaptic folds (fig. 6). The 
reduction of AChRs and the morphological changes 
observed in myasthenic end-plates compromise 
neuromuscular transmission. If this is reduced to the 
extent that the threshold value is not reached, action 
potentials will not be triggered. This will ultimately 
lead to the reduction of muscle power leading to muscle 
weakness and susceptibility to fatigue that is 
characteristic of MG.
1.3.1. Autoimmune nature of MG.
The autoimmune nature of MG was first suggested by 
Smithers (1959) on the basis of histological 
similarities between the thymus gland in MG patients and 
the thyroid of patients with Hashimoto's Thyroiditis. 
Simpson (1960) had also noticed associations between 
MG and known autoimmnune diseases and postulated that MG
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— shallow post synaptic folds
-  reduced numbers of AChRs
-  remaining AChRs have antibody bound
-  complement mediated lysis of
post synaptic membrane
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was caused by antibodies to the receptive substance at 
the motor end-plate. Other immunological features 
relating to MG were also discovered: Nastuk and co- 
workers observed wide variations in serum complement 
levels in MG patients (Nastuk et al. , 1960), while 
Strauss et ad.(1960) reported the presence of serum 
complement-fixing antibody bound in vitro to skeletal 
muscle sections. The latter study was the first 
demonstration of a circulating tissue-specific antibody 
related to MG. These antibodies were later shown to be 
connected to a tumour of the thymus, however, and not 
specific to MG (Oosterhuis et al,, 1976; Limburg et a l . 
1983).
That the AChR is the target of the autoimmune attack 
in MG was indicated by the serendipitous experiment of 
Patrick and Lindstrom (1973), who immunised rabbits with 
purified piscine AChR and observed severe myasthenia­
like symptoms in the animal. This experiment, coupled 
with those of other workers (Sugiyama et a l ., 1973; 
Heilbronn and Mattson, 1974) provided an experimental 
model (experimental autoimmune myasthenia gravis, EAMG) 
for further study of the human disease.
Antibodies to skeletal muscle AChRs, were found 
after Almon et al. (1974) demonstrated that 
approximately 50% of myasthenic sera tested could 
inhibit a-BGT binding to rat denervated preparations. 
The serum factor was later identified as IgG (Almon and 
Appel, 1975). Bender et ad. (1975), using indirect 
immunoperoxidase techniques, showed that myasthenic sera
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blocked the binding of a-BGT to motor end-plates of 
normal human muscle. The ability of a high proportion of 
myasthenic serum antibodies to fix complement in the 
presence of small quantity of Torpedo AChR was also 
demonstrated (Aharanov et a_l. 1975).
A radioimmunoassay for the quantitation of anti-AChR 
antibodies in MG sera soon became a standard diagnostic 
procedure (Lindstrora et a_l. , 1976; Lindstrom, 1977;
Monnier and Fulpius, 1977; Newsora-Davis et a_l., 1978; 
Dwyer et ad.,1979; Tindall et a l ., 1981; Carter et ad.,
1981). This procedure uses crude detergent extracts of 
human limb muscle as the source of AChR antigen. The 
detection of positive serum anti-AChR antibody levels is 
specific for the diagnosis of MG and approximately 90% 
of patients have elevated levels relative to controls 
(Lindstrom et ad., 1976; Lindstrom, 1977; Mittag et ad., 
1981, 1984; Monnier and Fulpius, 1977; Ito et a_l., 1978; 
Lefvert et ad., 1978).
1.3.2. Anti-AChR antibody characteristics.
The anti-AChR antibodies found in MG sera are 
predominantly of the IgG fraction (Rodgaard, et ad.,
1987), although antibodies of the IgM class have been 
reported (Lefvert et ad., 1978). In individual MG 
patients, anti-AChR antibodies of different IgG 
subclasses have been identified (Vincent and Newsom- 
Davis, 1980; Lefvert et a_l. , 1981; Tindall, 1981,
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Whiting et ad., 1983; Rodgaard et <al. , 1987). A small 
proportion of anti-AChR antibodies in MG are directed 
against the a-BGT binding site (Dwyer et a_l. , 1979; 
Mittag et ad., 1981; Vincent and Newsora-Davis, 1979, 
1980, 1982; Whiting et a l ., 1983).
These findings indicate that the antibodies are 
polyclonal, being directed to more than one determinant 
on the AChR of skeletal muscle. Monoclonal antibodies 
have been produced which bind to a variety of sites on 
the AChRs (Tzartos and Lindstrom, 1980). Most, however, 
bind to a region on the a subunit distinct from the 
cholinergic binding site, known as the main immunogenic 
region (MIR) (see Section 1.2.5.), and the use of such 
monoclonals in competitive binding studies has shown 
that the majority of human anti-AChR antibodies are 
directed at the MIR. Some antibodies are directed at 
other sites on other subunits and only a few are 
directed at non-MIR regions on the a subunit (Tzartos et 
al., 1982, 1983).
The heterogeneity of the antibodies in MG most 
probably helps to explain the well documented lack of 
correlation between clinical status and serum anti- AChR 
antibody titres (Lindstrom et a_l., 1976; Ito et a l . ,
1978; Lefvert et a_l., 1978).
1.3.3. Pathogenicity of anti-AChR antibodies.
It is generally accepted that depletion of AChR
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constitutes the major factor leading to impaired 
neuromuscular transmission in MG, and that anti-AChR
antibodies play an important role in this depletion. 
Whether the circulating anti-AChR antibodies are
pathogenic, or represent a secondary response to damage 
caused by some other agent, is important in
understanding the pathogenesis of MG.
The following observations support the idea that 
humoral factors are the primary agents in the disease 
process;-
i) Plasmaphoresis of myasthenic patients is 
associated with temporary clinical
improvement, paralleled by a decrease in the 
concentration of serum antibodies. (Pinching 
et a l ., 1976; Dau et ad., 1977; Newsom-Davis
et a l ., 1978) .
ii) Placental transfer of anti-AChR antibodies 
from myasthenic mother to fetus can cause transient 
neonatal MG, which remits as the titre declines. 
(Keesey et a l ., 1977).
iii) Injection of mice with myasthenic IgG 
produces the clinical symptoms of the disease 
associated with a reduction of mepps and a-BGT 
binding (Toyka et al., 1977).
If the anti-AChR antibodies are to cause synaptic 
dysfunction, they are required to leave the vascular 
system, diffuse into the extracellular space, enter the 
synaptic cleft and reach the AChRs on the synaptic
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folds. Detection of IgG at the motor end-plates in MG 
patients was achieved in an elegant study, by Engel et 
a l . (1977) using peroxidase-labelled Staphylococcal
Protein-A. These facts support the idea that the serum 
antibodies are one of the primary agents in the disease 
process.
The mechanisms by which this might be achieved are:
a) Direct immunopharmacological blockade of 
acetylcholine binding.
b) Accelerated degradation of AChR.
c) Lysis of the post-synaptic muscle membrane, 
possibly enhanced by complement.
The first two mechanisms have been extensively 
studied (for reviews see Vincent, 1980; Harrison and 
Behan, 1986), but there has been little investigation of 
the third mechanism.
1.3.4. Complement.
Complement is a series of nine protein components 
(1-9), present in the serum in an inactive form (for 
reviews see Alexander and Good, 1977; Lachmann and 
Peters, 1982). Several of the components are pro­
enzymes, awaiting the activation of their predecessor in 
the sequence to convert them into their active form, 
frequently by a proteolytic step. All the components 
initiate effector mechanisms which can produce a rapid 
amplified response to a trigger stimulus.
There are two main pathways of complement
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activation (see Fig. 7). The classical pathway, which is 
initiated by Clq (one of the components of Cl) binding 
to antigen-antibody complexes, and the alternative 
pathway, which is initiated in the absence of antibody 
by such stimuli as zymosan a yeast cell wall 
polysaccharide, cobra venom factor and properdin. When 
C9, the terminal component of the complement pathway is 
activated by the classical or alternative pathways, 
transmembrane channels are produced in susceptible 
membranes. These channels permit loss of intracellular 
constituents, entrance of extracellular ions and
osmotic lysis of the cell or membrane bearing the 
complex. Fig. 8 shows a diagrammatic representation of 
the mechanism of action of complement in MG. The
complement system plays an important role in
inflammatory and immune reactions, and in the
destruction of cells and cell membranes via complement- 
mediated lysis.
1.3.5. Involvement of complement in MG.
Involvement of complement in MG was first suggested 
by Nastuk et al. (1960), who noticed that serum 
complement levels fell during exacerbation of the
disease and proposed that complement was bound to 
antigen-antibody complexes on myasthenic end-plates, 
thereby reducing levels in the serum. This observation 
followed an earlier study by Nastuk et al. (1959) who
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FIG. 8 Proposed mechanism of complement in myasthenia gravis
S p e c if ic  p ro te o ly t ic  fragm ents  o f  com plem ent are
re leased  during th e  co m p lem en t c a s c a d e  which induce 
phago cytic  m igration  to  th e  end p la te
C4a C2 C3a C5a
Membrane atiack complex
Binding C 8  causes membrane dam age  
and po lym erisa tion  of C 9  forming a
Autoantigen
tubular transm em b rane  complex responsible
Muscle end plate
fo r the  u ltra s tru c tu ra l  m em brane lesion
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found that 2 out of 22 myasthenic serum samples were 
cytolytic to frog muscle in vitro, although control sera 
showed some cytolytic activity after a longer incubation 
period. Liveson et al. (1976) also noticed a cytolytic 
effect of myasthenic sera on mouse muscle cells in 
culture and its abolition by heating the sera 
(destroying any complement activity). However, other 
studies of this nature failed to demonstrate a 
complement mediated lytic effect (Harvey et ad. 1978) 
even when IgG and C3 were demonstrated by 
immunofluorescence to be bound to the cells (Lennon, 
1978).
Ultrastructural and light microscopic studies by 
Engel et ad. (1977) using peroxidase labelled 
Staphylococcal Protein-A and rabbit anti-(human-C3) 
antiserum, showed the presence of IgG and C3 on the 
muscle end-plates of myasthenic patients. In a 
continuation of these studies (Sahashi et ad., 1980) 
showed the presence of 09 on the muscle end-plates and 
of IgG, 03 and 09 on disintegrating junctional folds 
and on the debris in the synaptic cleft. These studies 
provided the first evidence for antibody dependent 
complement-mediated injury to the post-synaptic membrane 
in MG. Using similar techniques, Engel and Arahata 
(1987) have more recently demonstrated the presence of 
the MAC at the end plates of seven myasthenic patients. 
The latter evidence is probably the strongest with 
regard to the simplification and remodelling of the 
post-synaptic membrane in MG (see Fig. 6).
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The involvement of C3 in EAMG, passively transferred 
to mice by injection of myasthenic IgG was investigated 
by Toyka et al_., (1977). Animals first treated with 
cobra venom factor to deplete 03, showed a reduction in 
mepp amplitudes and a-BGT binding to muscle end-plates 
was less marked than in untreated animals. C3 depletion 
was also found to minimise the effects of passive 
transfer of EAMG by myasthenic serum to rats (Howard and 
Sanders, 1980). C5 was inferred not to be involved in 
EAMG, as genetically 05 deficient mice reacted similarly 
to non 05 deficient controls when injected with 
myasthenic IgG (Toyka et ad., 1977).
Direct experimental evidence of complement- 
mediated lysis in the human disease is lacking. A major 
reason for this probably lies in the difficulty in 
identifying and quantifying muscle cell lysis.
It is known that skeletal muscle cells, in culture, 
express a surface AChR, the appearance of which 
coincides with the fusion of myoblasts to form myotubes. 
Such cultures have been used to investigate complement 
mediated damage, evidence for which which has depended 
on either a visual assessment or release of 
radiolabelled chromium. Both methods have been 
criticised; the first can only detect gross disruption 
and the second lacks specificity, in that radiolabelled 
chromium is taken up not only by the cultured myotubes, 
but also by the fibroblasts which accompany them in 
culture. The proportion of fibroblasts can be reduced by 
the use of cytotoxic drugs but they cannot be completely
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eliminated.
Cambridge and Stern (1981) published a procedure for
measuring myotube specific cytotoxicity based on the use
of radiolabelled carnitine. The method was designed to 
assay the myotoxicity of lymphocytes from patients with 
polymyositis, and depends on the selective uptake by
cultured myotubes of tritiated carnitine. The subsequent
loss of radioactivity can be taken as a measure of cell 
lysis. This procedure is less sensitive to the presence 
of fibroblasts, which take up carnitine five times 
slower than do myotubes (Cambridge and Stern, 1981).
This assay was used to advantage to demonstrate 
lysis, by myasthenic serum and complement, of chick 
myotubes (Bird, 1986) and of cultured rat myotubes 
(Childs et a l ., 1984, 1985, 1987). Ashizawa and Appel
(1985) confirmed these results in a similar release 
assay, using radiolabelled rubidium instead of 
carnitine. A preliminary study (Childs et al., 1985) 
showed that the lytic property of serum was lost if 
anti-AChR antibodies were removed on an antibody 
affinity column.
These results complement the ultrastructural 
studies of Engel and colleagues in indicating the 
probable involvement of complement-mediated lysis as a 
factor in the myasthenic disease process. A summary of 
reports concerning the involvement of complement in the 
pathogenesis of MG is given in Table 1.
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Table 1. Involvement of complement in MG and EAMG. 
Involvement of complement_______________________Reference
Cytolytic properties of MG serum 
towards frog muscle in vitro.
Reduction in serum complement
levels during exacerbation of disease.
Cytolytic properties of MG serum 
towards mouse muscle cells in vitro.
Light microscopic demonstration of 
IgG and C3 on myasthenic muscle end 
plates.
Reduction in mepp amplitudes and 
a-BGT binding after depletion of C3.
Immunofluorescent detection of IgG and 
C3 on cultured rat muscle cells.
Light microscopic demonstration of 
IgG and C3 on intact junctional folds 
of Lewis rats injected with IgG from 
EAMG rats.
C3 depletion found to minimise passive 
transfer of EAMG to rats.
Light microscopic demonstration of 
IgG, C3 and C9 on disintegrating 
junctional folds.
Complement mediated lysis of rat 
muscle cells in vitro.
Complement mediated lysis of rat 
muscle cells in vitro.
Complement mediated lysis of chick 
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1. 3 . 6 . Cellular involvement in MG.
The mechanisms that trigger the sensitisation to 
AChR and subsequently maintain the levels of
circulating anti-AChR antibodies are unknown. As in 
other autoimmune diseases, the immune system in MG is 
responding to a "self-antigen" in an inappropriate way. 
This could result from:-
1) An alteration in the antigen, causing it to be 
perceived as "non-self".
2) Abnormal regulation of the immune system, 
allowing it to respond to a normal antigen.
3) An exogenous antigen that resembles the relevant 
autoantigen and thus triggers an autoimmune 
response•
In MG, it is possible that the immune mechanisms 
involved are not always the same in different patients, 
although the target of the autoimmune attack is probably 
always the AChR.
The malfunction in MG may originate in the thymus 
gland. Castleman (1966), drew attention to a high 
incidence of thymoma and other pathological changes in 
the thymus of patients with MG. The thymus is 
responsible for the development of immunocompetent T- 
cells, which are involved in both regulatory and 
effector functions. Thymic myoid cells are known to 
express AChR (Wekerle et a J ., 1975; Kao and Drachman, 
1977) and may provide the initiating stimulus for
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lymphocyte production of anti-AChR antibodies. The 
recognition of thymic AChR as "non-self” could occur as 
a consequence of 1 or 2 listed above.
Thymic cells from patients with MG can spontaneously 
synthesise anti-AChR antibody in culture (Vincent et 
a l ., 1978) and are able to enhance anti-AChR antibody 
production by autologous blood lymphocytes (Newsom-Davis 
et a l ., 1981). Willcox et al. (1984) suggested that this 
enhancement could be mediated by antigen-presenting 
cells rather than by AChR-specific T-helper cells in the 
thymus•
It has been suggested that the relative proportions 
of T-suppressor and T-helper cells, which regulate 
antibody synthesis by B-lymphocytes, could be important 
in MG. Studies using monoclonal antibodies and indirect 
immunofluorescence as phenotypic markers for T-cells 
have concluded that there are decreased numbers of 
circulating suppressor cells in MG (Bahir et a^., 1981; 
Skolnik et a_l. , 1982). Decreased suppressor cell
activity has also been inferred from the impaired 
ability of myasthenic T-cells compared to normal 
controls, to inhibit anti-AChR antibody production by 
myasthenic lymphocytes (Shinomiya and Yata, 1981). The 
autologous mixed lymphocyte reaction (AMLR) involves the 
proliferation of T lymphocytes when co-cultured with 
autologous non-T cells and may reflect in vivo 
mechanisms of immune control. An investigation by 
Richards et al. (1986), found that the AMLR in 
myasthenic patients was significantly depressed compared
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to normal controls. The proliferative responses of T- 
cells from myasthenic patients to the mitogens 
Conconavalin-A and Phytohaemagglutinin-P were also found 
to be reduced. These results were, in part, interpreted 
in terms of defective suppressor cell functions in MG 
(Richards et al., 1986). In general, however, studies 
on specific T-cell populations in MG have proved 
inconsistent (for reviews, see Lisak et al,, 1985;
Harrison and Behan, 1986).
There are several reports of increased in vitro 
proliferative responses by myasthenic peripheral blood 
lymphocytes to purified electric fish or human AChR 
(Abramsky et al., 1975; Richman et al., 1976; Conti-
Tronconi et a_l. , 1977; McQuillen et a l . , 1983;
Hohlfield et al., 1984; Nickless, 1985) and fetal calf 
AChR (Nickless, 1985).
Early morphological studies reported the presence of 
lymphorrhages (collections of lymphocytes), surrounding 
necrotic muscle fibres in approximately 20% of 
myasthenic muscle biopsies (Engel and McFarlin, 1966, 
Woolf, 1966). However, there is no evidence that cell- 
mediated immune mechanisms are directly responsible for 
the altered end-plate morphology seen in MG. It is 
probable that the enhanced proliferative response in
vitro is indicative of an increased number and/or
activity of specific helper T-cells which interact with 
antigen presenting cells and B-cells to produce anti- 
AChR antibodies (Lisak et a l ., 1985)
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1.4. Tissue and cell culture.
The study of the development and function of the 
muscular system must at some point focus on the 
development and function of the individual cells. 
Although this is difficult to investigate in vivo, 
tissue culture permits the study of the individual cell 
types in an environment that minimises the multiple 
interactive events characteristic in the animal. 
Purified populations of muscle cells, or homogeneous 
populations derived from clonal cell lines, have 
provided preparations suitable for biochemical and 
electrophysiological analysis.
1.4.1. Muscle culture.
The discovery that explanted fragments of frog 
embryo nervous tissue survived in the presence of 
clotted lymph (Harrison, 1907) was a major breakthrough 
in tissue culture. These experiments not only provided 
the first use of tissue culture for the study of the 
nervous system, but also exemplified the potential 
inherent in tissue culture. Harrison*s techniques were 
subsequently adapted to include tissue from other 
species. Lewis (1915) described the behaviour of 
explants of chick embryo leg muscle in culture. Some 
outgrowths of this culture demonstrated spontaneous
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contractility in the absence of nerves. After the 
establishment of enzymic dissociation techniques 
(Moscona, 1952; Rinaldini, 1959), studies were made on 
embryonic skeletal muscle grown in monolayer cultures 
and the use of skeletal muscle cultures in cell biology 
and biochemistry has since flourished.
The use of dissociation techniques to establish 
monolayer muscle cultures offers several advantages over 
previous explant tissue culture type investigations. The 
cells grow and develop in a synchronous manner and such 
cultures are particularly appropriate for the 
biochemical analysis of myogenesis. The cells can be 
maintained under uniformly controlled conditions and may 
be subjected to a wide range of experimental 
interventions. Successful cultures have been prepared 
from skeletal muscles of several species, including 
chick, mouse, rat and human (for reviews, see Hauschka, 
1972; Yaffe, 1973; Konigsberg, 1979). Further work has 
concerned methods for growing human muscle in 
dissociated cell cultures (Yasin et al^ . , 1977; Blau and 
Webster, 1981). One of the main attractions of applying 
tissue culture methods to skeletal muscle is the 
potential of using human tissue to investigate muscular 
and muscle-related diseases.
1.4.2. Development of acetylcholine receptors.
Studies of embryonic muscle in vitro have 
demonstrated that many properties of differentiated
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muscle in vivo are reproduced in cell cultures. In both 
cases, a proliferating pool of mononucleated cells is 
the precursor of multinucleated muscle fibres 
(Konigsberg, 1963; Yaffe, 1969).
Using tissue culture, it has been possible to study 
the development of acetylcholine sensitivity in skeletal 
muscle and the mechanisms controlling the production and 
distribution of AChRs. The fusion of myoblasts and the 
formation of multinucleated cells is the biochemical 
signal that triggers the production of many muscle 
specific proteins including cholinoceptors. In support 
of this, many workers have reported little or no 
response to iontophoretically applied acetylcholine in 
undifferentiated, uninucleated cells in culture (Dryden, 
1970; Famborough and Rash, 1971; Harvey et aj^ . , 1979), 
sensitivity appearing only after the formation of 
multinucleated cells. However, binding of a-neurotoxins 
(Patrick et al., 1972; Prives and Patterson, 1974) and 
autoradiography (Powell and Famborough, 1973; Sytkowski 
et a l ., 1973; Blau and Webster, 1981) have revealed low
levels of AChRs on myoblasts, increasing rapidly after 
fusion. Moreover, a small population of myoblasts do 
differentiate to become sensitive to acetylcholine 
(Famborough and Rash, 1971; Dryden et a l ., 1974) and 
this process can be increased by blocking fusion with a 
low Ca + + medium (Famborough and Rash, 1971).
On young myotubes, acetylcholine sensitivity and 
toxin binding sites are uniformly distributed. On 
further development, areas of high sensitivity and toxin
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binding can be detected (Vogel et ad., 1972), with 
clusters of binding sites (hot spots) increasing as 
myotube development proceeds (Sytkowski et ad., 1973). 
However, with increasing age in culture, there is a 
gradual disappearance of receptor clusters (Axelrod et 
ad., 1976: Prives et ad., 1976 ) ascribed to an effect
of muscle contractility.
1.4.3. Cell Lines.
Cell lines are particularly convenient as 
experimental models, providing consistent and 
reproducible systems.
In order to exploit clonal cell lines for the study 
of biological problems, a collection of cells is 
required that is representative of the in vivo cell 
types. A number of cell lines have been described, some 
obtained by selectively cultivating tissue samples [eg: 
the clonal cell line, L6 (Yaffe, 1968); the mouse C2 
cell line (Yaffe and Saxel, 1977 ); the BC3H1 cell line 
(Schubert et al_. , 1970) 1 and others derived from
spontaneous or chemically induced neoplasms [ PC12 cells 
(Greene and Tischler, 1976), IMR32 cells (Tumilowicz et 
ad., 1970) and TE671 cells (McAllister et ad., 1977)1.
1.4.4. TE671 cell line.
The human medulloblastoma clonal cell line TE671,
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was thought to be derived from a primitive 
neuroectodermal tumour of the cerebellum, sharing neural 
tube origins with other cells of the central nervous 
system (McAllister et al., 1977). Cerebellar
medulloblastoma is a rare central nervous system tumour 
type made up of cells that express a modicum of neuronal 
properties (Rorke, 1983). However, more recent findings 
dispute the neuronal origin of the cells (see Section
1.13.4.8. ) .
1.4.4.1♦ Cellular morphology.
There is evidence that the cell line is polymorphic 
in culture, exhibiting 5 (Syapin et a_l., 1982), or 6
(Zeltzer et al., 1984) morphological cell types (Table
2). All cell types are present at all stages of culture 
in varying proportions (Syapin et al ., 1982), although 
as the cells reach confluence, morphological definition 
becomes less apparent. It has been suggested (Lukas, 
1986a) that transitions in TE671 cellular morphology are 
a consequence of the passage of individual cells 
through the replication sequence.
1.4 . 4.2 . Pharmacological profile.
Syapin et a_l. (1982) established that all cell 
types were capable of generating Na+ dependent action 
potentials and further demonstrated that four out of the 
five cell types showed changes in conductance as a
Table 2. Morphological types of TE671 cells.
Cell Syapin et al^ . (1982) Zeltzer et al. (1984)





2 Small round or poly­
gonal cells.
Circular or round 
shaped cells.
3 Long centripolar 
bipolar spindle










6 — Giant multinuclear 
cell •
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response to iontophoretically applied acetylcholine but 
not to T-aroinobutyric acid (GABA), indicating the 
presence of functional AChRs. Fluorescent labelling 
studies (Luther et al. (1989) have also indicated that 
AChRs are present on the surface of some cells, 
although these experiments were carried out on serum 
starved TE671 cell cultures and it is not known what 
effect serum starvation may have on AChR expression.
The acetylcholine induced depolarising response was 
found to be inhibited by low concentrations of nicotinic 
antagonists, a-BGT (10~6M) and d-tubocurarine (10_5M) 
and only by high concentrations of the muscarinic 
antagonist, atropine (Syapin et ad., 1982). The fact 
that the depolarising response in TE671 cells is blocked 
by low concentrations of a-BGT, contrasts with the 
ineffectiveness of a-BGT in other cultured mammalian 
neuronal cell types (Patrick and Stallcup,1977).
Owing to the fact that the AChR family includes 
muscle type AChRs, neuronal AChRs and neuronal a-BGT 
binding proteins (see Section 1.2.6.), all of which 
exhibit related but distinct biochemical properties, the 
TE671 cell AChRs were initially classified as neuronal 
AChR types which could be blocked by a-BGT (Syapin et 
ad., 1982). This was clearly unusual and stimulated 
further investigation.
Lukas (1986abc) noted that [125I1 a-BGT binding 
sites on TE671 cells were unique in neuronal terms, 
bearing more similarity to sites on rat muscle or 
Torpedo electroplax than to those of PC12 cells or rat
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brain. These findings accord with those of de la Garza 
et al . (1987), who showed a-BGT to be effective in
antagonising cerebellar interneuron excitation by 
nicotine, in an essentially irreversible manner, 
suggesting that nicotine action in the cerebellum may be 
mediated by receptors similar to those at the 
neuromuscular junction.
A pharmacological similarity of TE671 cell AChR and 
that of muscle (human calf) was also noticed by Walker 
et a l . (1988). These workers noted, in addition, that
properties of AChRs in total TE671 cell extracts may be 
different from those present on the surface of the 
cells. Varying sensitivities to cholinergic antagonists 
were observed, which may reflect the stage of confluence 
of the cells (Lukas, 1986a).
1.4.4.3 . Immunological reactivity.
Immunological reactivity was investigated, initially 
by Lukas (1986abc), using the rationale that antibodies 
raised against AChR from electric organ or muscle might 
recognise highly conserved epitopes and so act as 
probes for a neuronal AChR. Immunological reactivity was 
further investigated by Lindstrom et ad. (1987) and by 
Whiting et a_l. (1987a), who found that the TE671 cell 
AChR bound antisera and monoclonal antibodies raised 
against both Torpedo and muscle and also that extracts 
of TE671 cell AChRs could bind serum from patients with 
myasthenia gravis containing anti-AChR antibodies.
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Lindstrom et a_l. (1987) also reported that extracts of
TE671 cells could be used in the immunoprecipitation
assay for anti-AChR antibody. The usefulness of the 
TE671 cell AChR as a reproducible source of antigen for 
this assay in myasthenia gravis has more recently been 
investigated by Walker et a_l. (1988), who found that the 
total number of binding sites available in TE671 cell
extracts is less than that found in many calf muscle
preparations, and concluded that the cell line offers no 
advantage as a source of antigen for the 
immunoprecipitation assay.
These data, overall, suggest that the AChR of TE671 
cell is similar or even identical to that of skeletal 
muscle, differences arising between the two receptors 
from post-translational modifications or from the 
vagaries of proteolysis (Whiting et ad., 1987a).
1.4.4.4. Electrophysiology.
A report, (Lindstrom et ad., 1988b, later published 
as Luther et ad., 1989) based on the 
electrophysiological analysis at the single channel 
level, indicated that AChRs on TE671 cells function like 
muscle AChRs and are blocked by a-BGT. Sine (1988) and 
Oswald et ad. (1988) observed similar
electrophysiological properties, confirming that the 
channel of TE671 cell AChR exhibited most of the general 
characteristics of electroplaque or skeletal muscle AChR 
channels, including those observed on cultured human
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muscle cells.
Combined data from Sine (1988) and Luther et al 
(1989) based on the channel properties and reaction with 
monoclonal antibodies against extrajunctional AChRs 
suggest that AChRs from TE671 cells have extrajunctional 
type AChRs rather than junctional AChRs.
1.4.4.5. Protein chemistry; AChR subunit composition.
Luther et al. (1989) have affinity purified AChR 
from TE671 cells on an a-BGT affinity column and found 
that it is composed of four polypeptides corresponding 
to a, 3, t and 6 subunits from Torpedo with apparent 
molecular weights of 42000, 52500, 55000 and 62000
Daltons. The acetylcholine binding sites were localised 
to the a-subunits, as shown by affinity labelling (see 
Section 1.2.4.4).
1.4.4.6. Molecular biology.
Work by Schoepfer et ad., (1988) involved the 
cloning and sequencing of cDNA for the a-subunit of 
AChRs from TE671 cells. The sequence showed extensive 
homology to that of a-subunits of muscle AChRs from 
several species and is identical to the sequence 
predicted from a human genomic clone previously reported 
(Noda et al. 1983c). Schoepfer et al. (1988) also found 
that the acetylcholine binding subunit of AChRs from 
TE671 cells is distinct from that found on rat neuronal
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AChRs and that sequence homology with PC12 cells and rat 
brain is lower than that for muscle. They concluded 
that the TE671 neuronal cell line expressed a-subunits 
identical to those of muscle rather than that of a 
neuronal type of AChR blocked by a-BGT.
1.4.4 .7 . AChR regulation.
\ jL ‘
Seigal and Lukas (1988) and Luther et aJL. (1989) 
noticed that regulation of TE671 cell AChR synthesis may 
differ from that of muscle cells. They observed that 
AChR expression is up-regulated by nicotinic agonists 
and sensitive to antagonists of a-BGT binding (Seigal 
and Lukas, 1988). This contrasts with muscle cells 
(Appel et al ., 1981; 1982) in which the receptor is
down regulated by prolonged agonist occupancy. Similar 
findings were reported by Robinson and McGee (1985) for 
AChRs of the neural-crest derived cell line PC12, 
although Whiting and Lindstrom (unpublished
observations) note agonist up-regulation of the PC12 
cell AChR. The mechanisms by which these agonists exert 
their effects are unclear, but regulation clearly varies 
in different cell types. It is possible that the TE671 
cell AChR is under a "neuronal" type of regulation that 




TE671 cells express extrajunctional muscle-like 
AChRs in relatively large amounts (Luther et <al. , 1989). 
Why should "muscle-like" AChRs be expressed in a 
neuronal cell line?.
Stratton et al_. (1989) very recently reported
several lines of evidence suggesting that the TE671 cell 
line was misidentified when initially reported by 
McAllister et al. (1977). DNA fingerprinting techniques 
have revealed that TE671 is identical to the
rhabdomyosarcoma cell line RD. Both cell lines were 
derived in the same laboratory but RD was described 
(McAllister et a_l. , 1969) before the first report of
TE671. These observations indicate that the TE671 cell 
line is most probably a subline of the rhabdomyosarcoma 
cell line RD, which would expain the presence of a
"muscle-like" AChR on TE671 cells.
1.5. Outline and aims of the project.
Most of the evidence implicating antibody-dependent 
complement-mediated destruction of the muscle end plate 
in MG is either indirect or based on animal cells in 
culture (see, Table 1).
Previous investigations in this laboratory used the 
carnitine release assay described by Cambridge and Stern 
(1981), the results indicated that myasthenic sera
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caused lysis of chick myotubes in culture (Bird, 1986) 
and rat myotubes in culture (Childs, 1985; Childs et 
al ., 1984,1985,1987) whereas normal sera treated
similarly did not.
In this project, using the same assay, the effects 
of myasthenic sera on fetal human skeletal muscle cells 
in culture were investigated. Human cultures proved to 
be an unreliable source of material for myotoxicity 
investigations so the studies were extended to include a 
human derived cell line (TE671) in culture. The results 
of this work are divided into two main sections: the 
first section describing studies on the cultured human 
muscle system and the second being concerned with TE671 
cell cultures. The overall aim of the project was to 
develop a human model system to monitor antibody- 




Carrier-free Na-[125I] in dilute NaOH (lOOmCi/ml) 
was from Amersham International Plcf Amersham, Bucks, 
U.K. and was stored at room temperature for not longer 
than 3 weeks after its activity reference date.
L-[Me-3H] carnitine hydrochloride <lmCi/ml, specific 
activity 87yCi/mmol) and Na 2 - 1 5 ^ -CrCU 1 in aqueous
solution (lmCi/ml) were purchased from Amersham 
International Pic as above.
Counting instruments.
[i2 si] was counted in an LKB 1280 Ultrogamma 
counter. Tritium and [51Cr] were counted in a tritium- 
specific channel in a Packard Tri-carb scintillation 
counter (Model 3255) for a 2 minute counting period. 
Correction for quenching was made using the channels 
ratio method. The efficiency of counting for tritium 
was 38% and for [51Cr] was 15%.
Ligands.
a-BGT from Bungaris multicinctus, decamethonium
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bromide, carbamylcholine chloride, d-tubocurarine 
chloride, hexamethonium bromide, choline chloride, 
acetylcholine chloride and atropine sulphate were 
obtained from Sigma Chemical Co., Poole, Dorset, U.K.
(-)-Nicotine hydrogen (+) tartrate was from BDH 
Chemicals, Poole, U.K.
Benzoquinonium chloride was a generous gift from 
Stirling Winthrop Inc., Renssalaer, New York, U.S.A.
Methyllycaconitine (MLA) citrate salt was a gift 
from Dr. M.H. Benn, Dept. Chemistry, University of 
Calgary, Alberta, Canada. (+)-Nicotine di-(-)-tartrate 
was provided by Dr. R. Barlow, Dept. Pharmacology, 
University of Bristol, Bristol, U.K.
Chemicals.
Standard laboratory reagents were from Sigma 
Chemical Co., Poole, Dorset, U.K. or from BDH Chemicals, 
Poole, Dorset U.K.
Gel filtration reagents were supplied by Pharmacia 
Ltd., Hounslow, U.K.
Ion-exchange resins, DEAE-cellulose filter discs, 
GF/C and GF/B glassfibre filter discs were from Whatman 
Lab. Sales Ltd., Maidstone, Kent, U.K.




Serum samples from normal volunteers (Table 3) were 
obtained from colleagues in the Department and from 
Southmead Hospital, Bristol, U.K.. Myasthenic serum 
samples were obtained from patients (Table 4) in several 
hospitals in the U.K. as samples received for the 
routine assay of anti-AChR antibodies. Plasma resulting 
from plasmapheresis and plasma-EDTA samples were also 
obtained from Southmead Hospital, Bristol, U.K.. Non- 
EDTA plasma and serum samples were stored frozen at 
-20°C, EDTA-plasma samples were stored at -80*C.
Goat anti-(human-IgG) antiserum was prepared in the 
Department by repeated intramuscular injections of
purified human IgG into a goat (Section 2.8.).
Rabbit anti-(fetal calf AChR) antiserum was a 
generous gift from Ms. S. Walsh of this Department.
Lyophilised guinea pig complement serum was 
obtained from ICN Immunobiologicals, Lisle, IL., U.S.A. 
(stated activity positive haemolysis at 0.07ml when the 
complement was at a 1/10 dilution), or from Flow
Laboratories, Irvine, Ayrshire, Scotland (stated 
activity CH /ml =250, where one CH is the amount of 
complement producing 50% lysis of sensitised sheep red 
blood cells under stated conditions). The serum was
reconstituted in the diluent provided and used
immediately.
Anti-C3c complement was from DAKO-immunoglobulins,
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Table 3. Details of normal controls used in this 
study•
Normal
human serum Age Sex Associated diseases
1 25 M None
2 27 M If
3 38 F IV
4 30 M IV
5 24 F II
6 47 M If
7 26 F If
Pool _
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Table 4. Details of myasthenic patients used in this 
study•




1 - F G - - 42.00
2 - F - - - a ) 20.60
b) 17.5
3 32 F S/G Tx IS a )71. 3
b ) 79.3
4 38 F S/G Tx IS,PX 10.90
5 21 M 0 T x - 0.26
6 - M - - - 9.00
7 64 M - - - 76.10
8 21 F - - - 9.60
9 62 F Crisis Thymoma - 8.58
10 66 F - - - 5.41
11 - F - - - 0.22
12 68 M* - - IS,Px 24.60
13 21 F - - IS 35.10
14 - M - - 54.00
15 51 F - - - 5.28
16 52 M - - - 1.04
17 19 F - - - 8.59
18 61 M — _ _ 6.26
G = Generalised myasthenia a)Frozen serum
S/G = Severe generalised myasthenia b)Fresh serum
0 = Ocular myasthenia
Crisis = Myasthenic crisis
IS = Immunosuppressive therapy
Px = Plasma exchange
T x = Thymectomy
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Denmark and rabbit anti-human C3d was from Southmead 
Hospital, Bristol, U.K.
Source of muscle AChR.
Human adult muscle was supplied by the Royal United 
Hospital, Bath U.K. and Bristol Royal Infirmary, 
Bristol, U.K., following lower limb amputations 
resulting from severe vascular disorders. Within 15 min 
of the operation, calf muscle was crudely dissected free 
from fat, tendon and skin, transported in ice, solid 
carbon dioxide or liquid nitrogen and stored at -80°C 
for up to six months.
Source of muscle and cells for tissue culture.
Human fetal tissue was obtained from fetuses 
(approximate age 8-16 weeks) from the Royal United 
Hospital, Bath, U.K., following pregnancy terminations 
by suction on a vacuum line. As soon as possible after 
the operation, the fetal limbs were placed in growth 
medium and stored at 4#C for up to 72h.
TE671 cells were kindly provided by Prof. J. 
Newsom-Davis, John Radcliffe Hospital, Oxford, U.K.
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Tissue culture reagents.
Dulbecco's modified Eagle's medium (DMEM) and 2.5% 
(w/v) crude trypsin solution, in Hank's balanced salt 
solution, were obtained from Flow Laboratories, Irvine, 
Ayrshire, U.K.
Donor horse serum (DHS) and fetal calf serum (FCS) 
were obtained from Gibco Ltd., Uxbridge, Middlesex, 
U.K. and were heat inactivated (56*C, 30min) before use. 
Penicillin (5000U/ml) and streptomycin (5000yg/ml) 
solution, L-glutamine (200mM), kanamycin (lOyg/ml), 
fungizone (amphotericin B, 250yg/ml) antibiotic- 
antimycotic solution (100X, lOOOOU/ml penicillin, 
lOOOOU/ml streptomycin and 25yg/ml fungizone) and 
trypsin-EDTA 10X, were obtained from Gibco Ltd., as 
above.
Deoxyribonuclease, hormones and co-factors were 
supplied by Sigma Chemical Co., Poole, Dorset, U.K. 
Glucose and sucrose (analytical grade) were obtained 
from BDH Chemicals Ltd., Poole, U.K. All reagents 
supplied in a non-sterile form were sterilised before 
use by passage of stock solutions through sterile 
filters (0.2ym) from Sera Lab., Crawley Down, W. Sussex, 
U.K. All sterile plastic ware used for tissue culture 
was supplied by Nunc Gibco Ltd., Uxbridge, Middlesex, 
U.K.
Nylon bolting cloth (0.53ym aperture) was from Henry 
Simon Ltd., Stockport, Cheshire, U.K.
All tissue culture procedures were carried out in an
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Intermed Pathfinder laminar flow cabinet.
Media.
The compositions of the tissue culture growth media 
and balanced salt solutions (BSS) used, were as follows:
Human muscle cell culture medium.
DMEM supplemented with:- 

























Glucose 6 • Og
Sucrose 15. Og
The above were made up to 1L with double distilled 
water containing 0.01M HEPES, final pH 7.3.




KH 2PO 4 l.lg
The above were made up to 1L with double distilled 
water.






NaHC03 0 • 35g
k h 2pcu 0 • 06g
MgCl2•6H20 O.lg





2.1. Iodination of a-BGT.
a-BGT was labelled with [125I] by the chloramine-T 
method (Hunter, 1967) as modified by Urbaniak et al. 
(1973). Carrier-free Na-[125I] (lOOmCi/ml) in dilute 
sodium chloride (20yl) was added to a-BGT (20yg,2.5nmol) 
in potassium phosphate buffer, pH7.5, (20yl), followed 
by chloramine-T (0.5% w/v) in 0.05M potassium phosphate 
buffer pH7.5 (lOyl). The mixture was stirred for 1 min. 
at 23#C, after which the reaction was terminated by the 
addition of 0.016% (w/v) sodium metabisuphate in 0.05M 
potassium phosphate buffer, pH7.5 <750yl), followed by
1% (w/v) carrier potassium iodide in the same buffer
(200yl) .
The labelled protein was separated from the
unreacted [125I] by passage through a column of Sephadex 
G-25 (25 x 1cm) previously equilibrated in 0.01M
potassium phosphate buffer pH7.5, containing 1% (w/v) 
BSA. Fractions (lral) were collected and aliquots (5yl) 
from each fraction were counted for radioactivity. The 
peak fractions containing [1 2 51 1 a-BGT were pooled and 
stored at 4#C for not longer than three weeks. The 
specific radioactivity of the [125I] a-BGT was 
calculated assuming 100% recovery of the protein.
A typical elution profile from the G-25 column is
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shown (Fig. 9), where it can be seen that approximately 
90% of the [12 51 ] was incorporated into the protein 
[range 75-98%; mean ± SEM (n): 90 ± 2.44% (10)]. The
specific activity was in the range 594-899 Ci/mmol [mean 
± SEM (n): 732 ±26 (10) Ci/mmol].
2.2. Biological activity of [125I] a-BGT.
The biological activity of the [12 51 ] a-BGT 
preparations was determined by measurement of the 
proportion of radiolabelled a-BGT that could be bound by 
a large molar excess of purified AChR from Torpedo 
marmorata.
Triplicate samples of Torpedo AChR (30pmol, lOOyl) 
in 0.01M potassium phosphate buffer, pH7.4, containing 
0.1% (w/v) BSA, 1% (v/v) Triton X-100 and 0.01% (w/v)
sodium azide, were incubated with the test radiolabelled 
a-BGT (0.5pmol, 50yl) for 90 min at 23°C in the presence 
and absence of excess unlabelled a-BGT (3yM).
Bound [ 1 2 si] a-BGT was separated from free toxin on DEAE 
cellulose filter discs essentially as described by 
Schmidt and Raftery (1973). Each sample was applied to 2 
DEAE-81 cellulose filter discs (diameter 24mm) 
premoistened with the above assay buffer and left to 
stand for 2 min. Samples were then vacuum filtered on a 
Millipore filter unit. The filters were washed (3 x 
lml) with the assay buffer and counted for 
radioactivity. Biological activity was calculated as 
follows:-




Biological activity = specific cpm bound (sample) x 100 
(%) total cpm added
The biological activity of the [125I] a-BGT 
preparations was in the range 32-60% [mean ± SEM (n): 47 
± 2.44% (10)].
2.3. Preparation of a crude extract of human AChR.
Detergent extracts of muscle were prepared from 
human adult legs according to the method of Stephenson 
et al. (1981).
Muscle (250g), was coarsely chopped and homogenised 
in a Waring blender at maximum speed (2 x 1 min.) in 
0.01M potassium phosphate buffer, pH7.4, (4 vols.)
containing ImM EDTA, 2mM benzamidine hydrochloride, 0.1M 
benzethonium chloride, O.lmM PMSF, bacitracin and 0.02% 
(w/v) sodium azide. The homogenate was centrifuged
(10000 g, 45 min, 4#C) and the resulting supernatant 
was decanted and discarded. The pellet was resuspended 
in the same buffer (1 vol.) containing additionally 2% 
(v/v) Triton X-100 (extraction buffer), stirred for 4h 
at 23*C and centrifuged (100000 g, 60 min., 4°C). The 
resulting supernatant was filtered through glass wool. 
This crude muscle extract was used in the
radioimmunoassay (Section 2.6.) for anti-AChR antibodies 
in human serum.
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2.4. Determination of AChR content of muscle extracts.
2.4.1. Ammonium sulphate precipitation.
The concentration of AChR from solubilised human 
muscle was determined by a method adapted from that of 
Meunier et al. (1972). Triplicate samples of human 
muscle extract (lOOyl) were incubated with 2.5nM [125I] 
a-BGT in extraction buffer <50yl) for 45 min at 23°C.
Specific binding of t125I] a-BGT was blocked in
parallel incubations containing ImM benzoquinonium 
chloride. Saturated ammonium sulphate was added to give 
a final concentration of 40% (w/v). After further
incubation for 16h at 4*C, the precipitates were 
collected on Whatman GF/C glassfibre filter discs, 
washed with 40% (w/v) saturated ammonium sulphate
solution (3 x 1ml) by vacuum filtration on a Millipore 
filter unit and counted for radioactivity.
Detergent extracts of human skeletal muscle, 
measured by the ammonium sulphate method, gave yields of 
0.26-3.9pmols [125I] a-BGT binding sites per gram of 
muscle (mean ± SEM (n): 1.41 ± 0.48 (6)).
Determination of AChR, in the extract, by using
precipitation with ammonium sulphate, gave high non­
specific binding. Accordingly an alternative method, 
adapted from Bruns et al. (1983) was investigated.
2.4.2. Polyethylenimine treated filter method.
Triplicate samples of human muscle extract were
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incubated as described above.
Non-bound toxin was separated from toxin-receptor 
complexes on polyethylenimine (PEI) pretreated Whatman 
GF/B glassfibre filters using a method adapted from 
Bruns et al. (1983).
A stock solution of PEI was made by diluting 
commercial 50% PEI free base 1:5 in PBS. Filters were 
soaked in fresh 0.3% PEI (1:33 dilution of stock 10% 
PEI) in PBS for l-24h before use. Samples were applied 
to the filters and washed with PBS (3 x 1ml) by vacuum 
filtration on a Millipore filter unit and counted for 
radioactivity.
Results obtained by using this method yielded much 
lower levels (10-20%) of non-specific binding than did 
the ammonium sulphate precipitation assay. The 
polyethylenimine assay is now routinely used in assaying 
AChR from purified muscle preparations.
In both methods (2.4.1. and 2.4.2.) sufficient
excess of [1251 a-BGT was ensured by repetition of the 
assay using serial two-fold dilutions of receptor in 
extraction buffer, when a linear relationship between 
dilution number and radioactivity should be obtained. 
The AChR content of the crude muscle extract was 
calculated in terms of [12 51 ] a-BGT binding sites as
follows:-
AChR = specific cpm x sample x 10
(pmol/ml) cpm/pmol [125I] dilution
a-BGT
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2.5. Preparation of rat brain P2 membrane fraction.
Brain tissue homogenate was prepared essentially as 
described by Gray and Whittaker (1962) with 
modifications by MacAllan et al. (1988).
Whole brains of adult Wistar rats (minus the 
cerebellum) were homogenised (10% w/v) in 0.32M sucrose 
solution, pH7.4, containing ImM EDTA, O.lmM PMSF and 
0.01% (w/v) sodium azide and the suspension was
centrifuged at 1000 g for 10 min. The supernatant was 
decanted and retained on ice. The pellet was resuspended 
in 0.32M sucrose (5ml/g original wet weight) and 
recentrifuged. The supernatants were combined and 
centrifuged at 12000 g for 30 min to give a P2 pellet. 
This was resuspended in 50mM potassium phosphate buffer, 
pH7.4, containing protease inhibitors as above, to give 
a final volume of 2.5ml/g original wet weight and washed 
twice by centrifugation and resuspension.
2.6. Radioimmunoassay of anti-(AChR) antibodies.
A radioimmunoassay procedure similar to that 
previously described (Lindstrom et al., 1976: Carter et
al., 1981) was used to determine the anti-AChR antibody 
content of fractionated serum samples. This procedure 
detects anti-AChR antibodies not directed at the a-BGT 
binding site.
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Detergent extract of human leg muscle (0.05pmol 
specific a-BGT binding sites) was labelled by incubation 
with excess [125I] a-BGT (0.5pmol) for 45 min at 23°C. 
Specific binding of [125I] a-BGT was blocked in parallel 
incubations with ImM benzoquinonium chloride. The 
resulting solutions were incubated in triplicate with 
serum or serum fractions (5yl) appropriately diluted 
with normal human serum, for 2h at 23#C (or 16h at 4#C). 
The labelled AChR-Ab complex was precipitated by the 
addition of goat anti-(human IgG) antiserum (35yl, the 
amount chosen to ensure maximum precipitation of the 
complex) and incubation for 2h at 23°C (or 16h at 4°C) 
(see Fig. 10). The resulting precipitates were collected 
by centrifugation (3000 g, 10 minf 4“C) and the pellets 
washed twice with lOmM potassium phosphate buffer, 
pH7.4, containing 0.15M sodium chloride, 1% (w/v) Triton 
X-100 and 0.1% (w/v) sodium azide (RIA buffer) by
alternate suspension and centrifugation, then counted 
for radioactivity. For each sample, maximum formation of 
[12 51 ] a-BGT antibody complexes was ensured by 
repetition of the assay using serial two-fold dilutions 
of the sample in order to obtain a linear relationship 
between the volume of undiluted sample and precipitated 
radioactivity. The anti-AChR antibody titre of serum or 
serum fractions is expressed as moles of specific [125I] 




Diagrammatic representation of the radioimmunoassay 
for anti-(AChR) antibodies.
AChR
+ l ,8S|] «-BGT
+ Anti-(AChR) antibodies in 
myasthenic serum




Titre = specific cpm sample x dilution factor 
(AChR) specific radioactivity 
cpm/pmol [125Il a-BGT
2.1. Purification of IgG.
IgG was prepared from normal and myasthenic serum by 
the method of Stevenson and Dorrington (1970), A 
solution of saturated ammonium sulphate (6ml saturated 
in 0.2M Tris-HCl, pH8.0) was added dropwise to normal or 
myasthenic serum (10ml) with stirring at 23°C. The 
solution was stirred for a further 30 min at 23#C and 
the precipitate was sedimented by centrifugation (500 
g, 15 min). The precipitate was dissolved in 30mM 
potassium phosphate buffer, pH7.3 (10ml) and dialysed 
overnight against the same buffer (4L). The non- 
dialysable material was applied to a column (20 x 2.5cm) 
of DE-52 cellulose pre-equilibrated with 30mM potassium 
phosphate buffer, pH7.3. The column was eluted with the 
same buffer and fractions (2ml) collected. Fractions 
showing absorbance at 280nm were pooled and 
concentrated on an Amicon B15 concentrator to the 
original volume of serum (10ml). The column was washed 
with 2M sodium chloride and re-equilibrated with 30mM 
potassium phosphate buffer before re-use. Purified IgG 
was stored at -20"C until required.
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2.8. Preparation of goat anti-(human IgG) antiserum.
Heat aggregated (60 min, 56#C) normal human IgG 
(Hagg), (1.0ml, 1.5mg/ml protein) was emulsified with 
Freund's complete adjuvant (1.0ml) and injected 
intramuscularly at one site in each hind leg of a goat. 
Repeated injections of Hagg in Freund's incomplete 
adjuvant were performed at 3 weekly intervals. A blood 
sample (10ml) was taken from the goat before each 
injection to allow the determination of goat anti-(human 
IgG) antibodies. When an adequate titre was reached, the 
goat was bled out. The blood was allowed to clot, at 
4°C, overnight then centrifuged (5000 g, 20 min, 4#C).
The serum was collected and stored at -20 *C in the
presence of sodium azide.
An adequate titre of goat anti-(human IgG) antibody
was where less than lOOyl of antiserum was needed to
effect total precipitation of [125I] a-BGT labelled 
AChR-antibody complex obtained by incubation of a fixed 
volume (5yl) of myasthenic serum, with a constant amount 
of [12 si] a-BGT labelled adult human AChR in the 
presence and absence of benzoquinonium chloride ( for 
details, see Section 2.6.).
A typical saturation curve is shown in Fig.11. 
Injections were repeated until an adequate titre was 
attained. In each of two goats, 3 injections were 
sufficient to achieve titres such that 35yl of antiserum 
effected precipitation of labelled AChR-antibody complex 



















FIG. 11 Saturation curve fo r the precipitation of receptor-antibody 





2.9. Estimation of C3 degradation products.
Barbitone buffer.
Solution A contained sodium barbitone (20.6g), EDTA 
(3.72g) in distilled water (500ml). Solution B contained 
barbitone (3.68g) boiled to dissolve in distilled water 
(250ml).
Solutions A and B were mixed, allowed to cool and 
the pH adjusted to 8.65 with 5M NaOH, before dilution to 
1 litre.
Buffer for electrophoresis chamber: dilute stock 1/2
Buffer for gel: dilute stock 1/4
Destain solution: water 450ml
methanol 450ml
glacial acetic acid 100ml
Protein stain: Brilliant Blue R (5g) in above
solvent, filtered prior to use.
Estimation of C3d in serum samples was measured by 
double decker rocket immunoelectrophoresis, similar to 
that described by Brandsland et ad. (1981), as modified 
by Bedwell et a l . (1986).
Agarose 1% (w/v) in barbitone buffer pH8.5 (see
above) and that containing additionally either anti C3c 
antiserum (DAKO immunobiologicals), (40yl/ml gel) or 
polyclonal anti-(human C3d), prepared at Southmead 
Hospital, Bristol, (50yl/ml gel) were prepared and 
stored in a water bath, at 56#C, immediately prior to
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use. The gels were poured onto Gel Bond film (Fig. 12) 
and allowed to set.
Myasthenic serum samples collected in EDTA (3yl) and 
five dilutions of a standard serum (3yl, prepared from 
normal human serum incubated at 37#C for 4h to allow the 
complete conversion of C3 to C3c and C3d) were applied 
to the gel. Samples were electrophoresed in an LKB 
Multiphor electrophoresis tank at 2.5V/cm overnight at 
4°C. After this time, the gel was removed, washed 
extensively in 0.14M saline and pressed. The gel was 
completely dried with a hair dryer before staining in 
Brilliant Blue R (2 min., 23°C) and destaining to give 
a colourless background.
Results are expressed as a percentage of the amount 
of C3d in the standard serum.
2.10. TISSUE CULTURE.
2.10.1. Human myotube cultures.
2.10.2. Preparation of tissue culture plates.
Collagen was prepared essentially according to
Erhman and Gey (1956).
A rat’s tail was washed in 70% ethanol for 30 min. 
The skin was removed and the tendons dissected out with 
bone forceps. The tendons were washed in distilled 
water and placed in 0.1% (v/v) glacial acetic acid
(100ml) at 4#C for 48h to extract the collagen. The 
resulting solution was centrifuged at 800 g for 2h at
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23#C. The resulting supernatant was diluted with 
distilled water to give a protein concentration of 
0.75mg/ml and stored at 4#C until required.
Tissue culture plates (24 well) were precoated with 
photo-reconstituted collagen gel according to the method 
of Masurovsky and Peterson (1973).
Collagen solution (0.75mg/ml) was mixed with 
riboflavin 0.05% w/v) in a ratio of 4:1 (v/v). A sample
of this solution (30yl) was spread over the surface of 
each culture well. The gel was photopolymerised by 
exposure to fluorescent light for lh in a laminar flow 
cabinet. Coated plates were dried overnight at 37#C. The 
plates were washed with sterile distilled water 
(1-1.5ml) for 2-3 min and incubated with growth medium 
for at least 30 min before the addition of cells.
2.10.3. Establishment of cultures.
Human myotube cultures were established using muscle 
tissue from the limbs of 8-16 week fetuses essentially 
according to the method of Yaffe (1973) for neonatal rat 
muscle cultures.
Limbs were washed in Ca++ and Mg++ free balanced 
salt solution (Puck's BSS, see ’’Materials") . Dissection 
of limbs was then carried out under a Swift binocular 
viewer at xlO magnification. After removal of skin, 
tissue surrounding the bone was stripped and placed in a 
35mm plastic petri dish containing Puck’s BSS, (0.5ml). 
The tissue was minced with a pair of irridectomy 
scissors to produce a slurry and transferred with
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washing to a sterile plastic tube (final volume 8.5ml). 
Deoxyribonuclease (lmg/mlf 0.5ml) was added to prevent 
cell clumping, induced by deoxyribonucleic acids 
released from dead cells. Crude trypsin solution (2.5% 
w/v, 1ml) was then added to give a final concentration 
of 0.25% (w/v). The tissue suspension was incubated at
37°C for 60 min. with periodic mixing. The suspension 
was then centrifuged at 400 g for 5 min, the 
supernatant was discarded and growth medium (5ml, see 
"Materials") was added to the resulting pellet. Any 
residual trypsin action was inhibited by the serum 
component of the growth medium. Cells were then released 
from the tissue fragments by gentle trituration with a 
glass pasteur pipette (15-20 cycles). The suspension was 
left to stand for 3 rain and the supernatant, containing 
free cells, was removed for filtering. Further growth 
medium was added to the remaining tissue and the 
trituration process was repeated.
The combined cell suspensions were filtered through 
two layers of nylon bolting cloth (53ym aperture) to 
remove remaining cell aggregates and tissue clumps. A 
sample of the filtrate was added to an equal volume of 
trypan blue (0.2% w/v in PBS) before counting in a 
haemocytometer.
Cells were added to collagen coated 24 well (15.5mra) 
culture plates at a final plating density of 2.5 x 105 
cells/well (1.3 x 106 cells/cm2) in growth medium (1ml).
Cultures were grown in a humidified atmosphere of 
10% C02/air. Growth medium was replaced by fresh, pre­
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warmed medium every three days. After 3-4 days growth, 
when fusion of myoblasts was judged morphologically to 
be complete, cytosine arabinoside (10yM) was added to 
the cultures for 72h. This mitotic inhibitor reduced the 
growth of fibroblasts in the cultures.
2.10.4. Carnitine assay: mytoxicity of serum and
complement.
L-[Me-3H]-carnitine hydrochloride of high specific 
activity (87yCi/mmol, radioactive concentration, 
lmCi/ml) was diluted, under sterile conditions, in 
growth medium to a final concentration of 0.23yM.
Quadruplicate myotube cultures in 24-well plates, 
prepared, as described above, were labelled by 
incubation with L-[Me-3H ]-carnitine for 18h at 37#C in 
an atmosphere of 10% C0 2 /air, after which the cultures 
were washed three times with growth medium (0.5ml, 2-3 
min). After washing, fresh medium was added to each 
culture well followed by the addition of heat 
inactivated test serum (0.08ml) and finally lyophilised 
guinea pig serum (0.08ml). The cultures were then 
incubated at 37#C in an atmosphere of 10% C02/air for 
3h. After the incubation, cultures were washed with 
growth medium (3 x 0.5ml, 2-3 min), solubilised with 
0.1M sodium hydroxide, mixed with scintillation fluid 
(Optiphase Safe, 5ml) and counted for radioactivity.
Control cultures to which no additions of test serum 
or guinea pig serum were also included in the test.
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Myotoxicity was expressed as the percentage loss of 
radioactivity, compared with controls, according to the 
formula:-
CRC - CRT x 100%
CRC
Where CRC = counts retained in control cultures to 
which no additions of serum were made.
CRT = counts retained in test cultures.
2.11. TE671 cell culture.
The TE671 cells were routinely cultured in growth 
medium (see "Materials") in 80cm3 flasks at 37#C in an 
atmosphere of 10% C02/air.
2.11.1. Preparation of tissue culture plates.
Tissue culture plates (24 well and 96 well) were 
pre-coated with polylysine solution (5yg/ml, 1ml)
overnight at 37°C. The polylysine solution was removed 
by aspiration and each well washed with sterile 
distilled water (1-1.5ml, 24 well plates; 100-150yl, 96 
well plates) for 2-3 min and incubated with growth 
medium for at least 30 min before the addition of cells.
2.11.2. Cell harvesting.
TE671 cells, in 80cm3 flasks, were harvested with 
trypsin-EDTA.
The medium above the cells was removed by
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aspiration and the cell layer washed gently with warmed, 
sterile PBS (10ml). The PBS was removed by aspiration 
and trypsin-EDTA (0.25% w/v trypsin, 2% w/v EDTA in PBS) 
was added to each flask for 30 sec, with agitation. The 
trypsin-EDTA was then removed by aspiration and the 
flasks were incubated for 5 min. at 37°C. TE671 cells
were collected in PBS (2 x 10ml) and a sample of the 
resulting suspension was added to an equal volume of 
trypan blue (0.2% v/v in PBS) before determining viable 
cell numbers in a haemocytometer. The cells were then 
centrifuged (500 g, 5 min), resuspended in fresh, 
warmed growth medium and seeded out into prepared tissue 
culture plates (as above) at cell densities of 5 x 105 
cells/ml (24 well plates) or 5-10 x 103 cells/lOOyl (96 
well plates). Any remaining cells were returned to 80cm3 
flasks for continuous culture, or stored frozen at 
- 80#C, in DMEM containing 50% (v/v) FCS and 20% (v/v) 
DMSO •
Protein was determined according to the method of 
Lowry et al . (1951), after washing the cells with PBS to 
remove growth medium and solubilisation of the cells in 
0.1M sodium hydroxide.
2.11.3.1. Characterisation of TE671 cell AChR.
2 .11. 3.2 . Determination of AChR content of intact and 
solubilised TE671 cell extract.
The concentration of AChR in intact and solubilised 
TE671 cells was determined by using a method adapted
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from Bruns et al. (1983).
Cells were harvested as described above and 
triplicate samples (lOOyl) of intact cells in PBS or 
cell extract in PBS containing additionally 1% (w/v) 
Triton X-100, were incubated with 2.0nM [125I] a-BGT in 
PBS (+/- Triton X-100) for 90 min at 23#C. Specific 
binding of [125I] a-BGT was blocked in parallel 
incubations using d-tubocurarine (l.OmM) or a-BGT (lyM). 
Non-bound toxin was separated from toxin receptor 
complexes on PEI pretreated Whatman GF/B glassfibre 
filters and the AChR content of the crude cellular 
extract was calculated in terms of [125I] a-BGT binding 
sites as previously described (Section 2.4.).
2.11.3.1. [12 si ] g-BGT binding to TE671 cells.
[l2 51 ] a-BGT binding was measured in intact cells. 
Cells were harvested, as previously described. Cells (5 
x 105) were replated in growth medium (1ml) in each well 
of a 24 well plate (15.5mm diameter). Binding was 
assayed the following day when the cells were firmly 
attached and judged morphologically to be confluent. 
(12 si] a-BGT in growth medium (0.5-10nM , final 
concentration) was added to the cells and incubated for 
2h at 37#C. Non-bound toxin was removed by aspiration of 
the medium, followed by washes with growth medium (3 x 
0.5ml). Non-specific binding was determined by pre­
incubating (30 min) the cells with d-tubocurarine 
chloride (ImM, final concentration). The cells were
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solubilised with 0.1M sodium hydroxide and counted for 
radioactivity in an LKB 1280 Ultrogamma counter. 
Specific [125I] a-BGT binding to the cultures was 
calculated from:-
total cpm - non-specific cpm
(-d-TC)__________ ( +d-TC)
cpm/pmol [12 51 ] a-BGT
2.11.3.4. Determination of apparent constants for 
inhibition by cholinergic ligands, of binding 
of [12 51 ] a-BGT to TE671 cells.
Cells were harvested and replated in fresh growth 
medium as previously described.
Triplicate wells were incubated with [12 51 ] a-BGT 
(20yl, 2.0nM final concentration) in the presence of
increasing concentrations of unlabelled cholinergic 
agents (lOOyl) for 90min, 37#C, with final 
concentrations as follows:-
a-bungarotoxin 1x10“10 —  2. 5x10“ 8M
decamethonium lxlO-0 —  lxlO“5M
d-tubocurarine lxio-8 -- 2 • 5x10“6M
benzoquinonium 2.5xl0“7 —  lxl0“*M
methyllycaconitine lxio-6 -- 2•5x10“4M
acetylcholine 1x10“7 —  2 • 5x10“5M
carbachol 2.5x10“® -- 1x10“5M
(-) nicotine 1x10“7 —  2 • 5x10“4M
(+) nicotine 2 . 5x10“7 —  1x10“4M
glutamate, glycine, atropine, choline and hexamethonium
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were all tested at a concentration of 1x10-3M.
After the incubation period, the medium above the 
cells was removed by aspiration, the cells were washed 
with growth medium <3 x 0.5ml) and extracted with 0.1M 
NaOH (2 x 0.5ml). The combined extracts were counted for 
radioactivity in an LKB 1280 Ultrogamma counter. The 
amount of binding was calculated, for each concentration 
point, and plotted, as a percentage of control binding, 
[determined in a parallel incubation using a molar 
excess of unlabelled a-BGT (lyM)], against log of 
displacing drug concentration.
2.11.3.5. Determination of apparent constants for 
inhibition by MLA, of [125I] a-BGT binding to 
various tissue preparations.
a ) Frog and human muscle extracts.
Detergent extracts of frog muscle (Rana pipiens) 
with a protein concentration of 15.5mg/ml were kindly 
provided by Dr. S. Wonnacott. Detergent extract of human 
muscle was prepared, as previously described (Section 
2.3. ) .
Triplicate samples of extract (500yl, 1.5mg/ml 
protein) were incubated with [125I1 a-BGT (20yl, 2.0nM) 
in the presence of increasing concentrations of MLA 
(20yl, 2.5xl0“7 —  lxlO”3M), 90 min, 23°C. After the
incubation, non-bound toxin was separated from toxin 
receptor complexes on PEI pretreated Whatman GF/B 
glassfibre filters and counted for radioactivity (for 
details, see Section 2.4.2.).
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b) Rat brain P2 membranes.
Rat brain P2 membranes were prepared as previously 
described (Section 2.5.). Binding of [125I] a-BGT to 
these membranes was assayed essentially as described by 
Schmidt (1977).
The membrane fraction was diluted 10-fold in 50raM 
potassium phosphate buffer, pH7.4, and triplicate 
samples (0.5ml) were incubated with [1251 ] a-BGT (20yl, 
2.0nM) in the presence of increasing concentrations of 
MLA (20yl, 2.5xl0-11 -- lxlO_8M), for 3h at 23°C. After 
the incubation, non-bound toxin was separated from toxin 
receptor complexes by centrifugation (2 min, 10000 g) 
in an MSE Microcentaur bench centrifuge. The pellet was 
washed once with ice-cold PBS and counted for 
radioactivity as above.
The amount of specific binding for each 
concentration point was calculated and plotted as a 
percentage of control binding determined in parallel 
incubations using a molar excess of unlabelled a-BGT 
(lOyM) against log displacing drug concentration.
2.11.3.5. Inhibition of t125I] a-BGT binding to TE671 
cells by myasthenic serum.
Cultures were set up as for [125I] a-BGT binding 
(Section 2.11.3.3.). An additional pre-incubation step
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with myasthenic serum (the dose range of which was 
dependent on the anti-AChR antibody titre) was 
introduced after the incubation with d-tubocurarine 
chloride. Control wells to which no serum or normal 
human serum was added, were included in each test. The 
cells were washed, solubilised and counted for 
radioactivity as previously described.
Inhibition of [125I] a-BGT was determined as 
follows:-
specific cpm test serum x 100%
specific cpm control serum
2.11.4. TE671 cell cytotoxicity studies.
2.11.4.1. Lactate dehydrogenase [EC 1.1.1.27] assay.
The presence of LDH [EC 1.1.1.27] in TE671 cells was 
detected using a colorimetric assay based on that 
described by Bergmeyer and Bernt (1974) (Fig.13).
Cells were harvested as previously described 
(Section 2.11.2.) but resuspended in Hank's BSS (HBSS), 
containing additionally Triton X-100 (2% v/v). This
suspension was serially diluted in HBSS and 
quadruplicate samples (lOOvl) were plated into each well 
of a 96 well plate (6.0mm diameter). Lactate solution, 
containing lactate, 5.4xlO”2M; p-iodonotrotetrazolium 
violet, 6.6xlO_4M and phenazine methosulphate, 2.5xlO“4M 
in distilled water (25ml) was diluted (five-fold) in
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Fig. 13. Principle of the colorimetric assay for LDH 
using lactate, NAD*, phenazine methosulphate 
and p-iodonitrotetrazolium violet.
(1) Lactate + NAD* Pyruvate + NADH + H*
J '
(2) NADH + Phenazine + H* >NAD* + Reduced phenazine
methosulphate methosulphate
t
(3) Reduced + Tetrazolium----- ►Formazan + Phenazine
phenazine salt product methosulphate
methosulphate
93
0.2M Tris-HCl, pH8.2 and lOOyl was added to each well, 
left for 15 min at 23#C. The reaction was terminated by 
the addition of isopropanol, containing 4% (v/v) 1.0M
HCl (50yl). The plates were read immediately at 495nm in 
a Titertek Multiskan MCC/340 plate reader.
2.11.4.2. Cytotoxic effects of myasthenic serum and GPC 
on TE671 cells.
TE671 cells were harvested and replated as 
previously described.
Quadruplicate cell cultures in 96-well plates were 
washed with HBSS (2 x 50yl). After washing, fresh HBSS 
was added to each well (80yl), followed by the addition 
of myasthenic serum (lOyl per well) and finally GPC 
(10yl). The cultures were then incubated at 37#C in an 
atmosphere of 10% C02/air for 3h. After this time the 
medium above the cells was transferred to a clean 96- 
well plate and assayed for LDH presence as previously 
described.
Control cultures, to which either normal human 
serum, no serum or complement, or each component alone 
was included in each test. Cytotoxicity was expressed as 
the percentage LDH released from test sera with or 
without complement, with respect to LDH released from 
Triton X-100 lysed cells, also included in the test.
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2 .11.4.3. Selective inhibition of endogenous serum LDH.
a ) Using DEAE Sephadex A-50.
DEAE Sephadex A-50 (lg) was suspended in 20mM sodium 
phosphate buffer, pH6.8, (50ml), mixed thoroughly and
allowed to sediment for 45 min at 23#C, after which 
time the buffer was decanted from the sedimented 
material. The suspension and decanting procedure was 
repeated three times, the resulting uniformly fine 
sediment was resuspended in buffer to give a final 
volume of 50ml.
DEAE Sephadex A-50 (1ml) was then mixed with serum 
(lml) for lOmin 23°C. This suspension was centrifuged 
(3000 rpm, 5 min,23*C) and the supernatant was retained 
for testing in cytotoxicity assays and RIA for anti-AChR 
antibody titre.
b ) Using Matrex Blue-gel.
Serum samples were applied to a mini-column 
containing Matrix Blue-gel (lml) and recirculated for 1 
h at 23°C, after which, the eluant was retained for 
cytotoxity tests and RIA, as described above.
2.11.5. Determination of uptake of a) L-[Me-3H] 
carnitine hydrochloride and b) [51Cr] by TE671 
celIs.
TE671 cells were harvested and replated as
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previously described. L-[Me-3H] carnitine hydrochloride 
(specific activity 87yCi/mmol, radioactive
concentration, lmCi/ml) or [51Cr] (radioactive 
concentration, lmCi/ml) were diluted under sterile 
conditions in growth medium, before addition to 4 
replicate culture wells (0-10yM, carnitine;
0-0.2yCi/ml,** chromium).
After incubation (18h, 37°C in an atmosphere of 10% 
C02/air), the cultures were washed (3x0.5ml growth 
medium), immediately extracted in 0.1M NaOH (2x0.5ml) 
and mixed with scintillation fluid (Optiphase safe, 
5ml). The radioactivity of each culture well was 
determined by counting in a Packard Tricarb liquid 
scintillation counter.
** later increased (0-20yCi/ml).
2.11.5.1. Cytotoxicity of serum and complement on 
TE671 cells in culture.
Quadruplicate wells of TE671 cells were labelled by 
incubation (18h, 37#C) with [51Cr] (2.5yCi/wel1), in an 
atmosphere of 10% C02/air. Cultures were then washed 
with growth medium (3x0.5ml, 2-3 min) and fresh medium 
(0.5ml) was added to each well, followed by the addition 
of heat inactivated serum +/- guinea pig complement. The 
cultures were then further incubated at 37°C for 3h. 
After incubation, cultures were washed with growth
medium (3x0.5mlf 2-3min), extracted with O.lM NaOH (2x
0.5ml), mixed with scintillation fluid (Optiphase safe) 
and counted for radioactivity as previously described.
Control cultures to which no addition was made were 
included in the test. Cytotoxicity was expressed as the 
percentage loss of radio activity compared with 
controls, according to the formula 
CRC - CRT x 100%
CRC
where CRC = counts retained by controls.
CRT = counts retained by test.
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RESULTS.
3.1. Human skeletal muscle cells in culture.
3.1.1. Preparation of cultures.
Single cell suspensions were prepared from human 
fetal limbs as described in Section 2.10.3. 
Dissociation of tissue with 0.25% (w/v) trypsin for lh 
at 37°C resulted in cell yields of 1.0-1.8x10® cells/ 
limb. Subsequent dissociation, employing additionally 
0.25% (w/v) collagenase, resulted in slightly improved 
yields 0.5-3.5x10® cells/limb (Table 5), the latter 
procedure was routinely used. Cell viability, as judged 
by the exclusion of trypan blue dye, was greater than 
95%.
As human muscle cells in culture were very 
susceptible to bacterial and fungal infection, 
reflecting the conditions involved in collection of the 
fetuses, limbs were routinely collected and stored in 
growth medium containing penicillin and streptomycin 
(lOOOOU/ml) and fungizone (2.5yg/ml). Of 16 human 
muscle culture preparations, only five were viable for 
subsequent assay.
3.1.2. Morphology of cultures.
After several hours in culture, most of the cells 
were attached to the collagen substratum. The 
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1 - 2  days in culture, spindle-shaped, bipolar cells 
could be distinguished from flat, multipolar cells. The 
morphology of the former is attributed to cells of 
myogenic origin and that of the latter is typical of 
fibroblasts.
The cultures then entered a period of rapid cell 
fusion resulting in the formation of a network of 
rapidly growing multinucleated fibres or myotubes (Fig. 
14) .
3.1.3. Inhibition of fibroblast growth.
After 3-4 days in culture, when fusion of 
myoblasts was judged morphologically to be complete, a 
mitotic inhibitor, cytosine arabinoside (lOyM, final 
concentration) was added to reduce fibroblast growth. 
Cytosine arabinoside did reduce the fibroblast growth 
but also resulted in poor myotube growth.
3.1.4. Myotoxicity studies: Effect of serum and
complement on human muscle cultures.
A preliminary myotoxicity study investigated the 
effects of heat inactivated (56#C, lh) pooled normal 
human serum and a myasthenic serum sample (stored 
before use at -20#C for varying lengths of time) on 
human myotubes in culture.
Cultures in 24-well plates were labelled with L- 
[Me-3H] carnitine as described (Section 2.10.4.), before
Fig. 14
L i g h t  Pho tomic r og rap h s  of human muscle  c e l l s , Day 6 in  




use in the myotoxicity assay. By dividing the 24 well 
plate into six groups of quadruplicate tests (Fig. 15), 
labelled cultures were incubated with normal or 
myasthenic serum (80yl, 12% v/v) and/or GPC (80yl, 12% 
v/v) for 3h at 37°C. Myotoxicity was calculated as 
previously described (Section 2.10.4.). The myotoxicity 
given by pooled normal human serum was -4.25%, a 
corresponding value for myasthenic serum was -3.5%. 
Values for myotoxicity for serum with complement gave 
4.65% for pooled normal human serum and 6.04% for 
myasthenic serum.
In view of this apparent lack of relative toxicity 
of myasthenic serum, carnitine labelled cultures were 
incubated with increasing concentrations of heat 
inactivated serum (50 - 300yl, 3.3 - 20% v/v) in the
presence of a constant concentration of GPC (300yl, 20% 
v/v), or alternatively with increasing concentrations of 
GPC (50 - 300yl, 3.3 - 20% v/v) in the presence of a
constant concentration of serum (300yl, 20% v/v). From
Fig. 16 it can be seen that myotoxicity increased with 
increasing concentrations of myasthenic serum or GPC. 
Normal human serum had little effect in these 
experiments (myotoxicity <10%).
In further myotoxicity assays, human muscle 
cultures, labelled with L-[Me-3H] carnitine as described 
above, were incubated with an increased concentration of 
both serum and GPC (300yl, 20% v/v). Using these
conditions, the complement-mediated myotoxicities of 




Arrangement of myotoxicity test samples fo r 6 tests on 
a 24 well culture plate.
1 3 5 6 2 4
1 3 t; 6 2 4
2 4 6 1 3 5
2 4 6 1 3 5
1 = no addition 
2= normal human serum 
3= ”  " and GPC
4= myasthenia gravis serum 
5= " *' " and GPC
6= GPC
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Fig. 16. Myotoxicity of myasthenic serum on human 
muscle cultures.
a) effect of increasing serum concentration.
b)effect of increasing GPC concentration.
a) Seven day old human muscle cultures labelled 
with L-[Me-3H] carnitine were exposed to increasing 
concentrations of normal human serum (•) or a myasthenic 
serum (O), in the presence of GPC (0.3ml).
b) Seven day old human muscle cultures labelled 
with L-[Me-3H] carnitine were exposed to increasing 
concentrations of GPC in the presence of a fixed 
concentration (0.3ml) of normal human serum (•) or 
myasthenic serum (O).
Myotoxicity was calculated as previously described 



























were assessed (Fig. 17). The measured myotoxicity given 
by heat inactivated pooled normal human serum was in the 
range -14 —  8% (-2.8 ± 4.2% ; mean ± SEM (n=5)).
Corresponding values given by heat inactivated
myasthenic serum samples were in the range -10 —  30% (5
± 7%; mean ± SEM (n=5)). Values for myotoxicity for
serum with complement were 11 -- 31% (17 ± 4%; mean ±
SEM (n=5)) for pooled normal human serum and 29 —  49%
(35 ± 3%; mean ± SEM (n=5)) for myasthenic serum
samples. Myotoxicity of GPC alone was 1 —  30% (16 + 5%; 
mean ± SEM (n=5)). The results for each individual 
myasthenic serum sample are shown in Fig. 17, where it 
can be seen that the combination of myasthenic serum and 
GPC gave higher myotoxicity values than for pooled 
normal human serum in the presence or absence of GPC, 
myasthenic serum alone or GPC alone. The measured 
complement-mediated myotoxicity of myasthenic sera did 
not correlate with their anti AChR antibody titre.
The results indicated a complement-mediated lysis 
of cultured human muscle cells by myasthenic serum. In 
view of the spread of myotoxicity values obtained (Fig. 
17) there was clearly a need for many more assays, but 
owing to the erratic supply of cells and the freqency 
with which contamination occurred, this was not
practicable. Accordingly, an alternative supply of human 
cells expressing AChR was sought.
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Fig. 17. Myotoxicity of serum and GPC on human 
muscle cultures.
Seven day old human muscle cultures grown in 
Dulbecco's modified Eaglefs medium, were labelled with 
L-[Me-3H] carnitine as previously described (Section
2.10.4.) and exposed to samples of heat inactivated test 
serum (300yl, 20% v/v) in the presence of GPC (300yl, 
20% v/v) for 3h at 37*C. Cultures to which no additions 
were made (control) or to which GPC alone (300yl, 20% 
v/v) was added were run simultaneously. At the end of 
the incubation time, the cultures were washed and 
solubilised for counting. Myotoxicity was calculated as 
described (Section 2.10.4.) by comparison with control 
cultures.
Results are the means for five different myasthenic 
sera tested in quadruplicate culture wells. The mean ± 
SEM for each group of tests is shown.
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3.2. TE671 CELL CULTURE.
3.2.1. Cellular morphology and growth characteristics.
In culture, TE671 cells consist mainly of polygonal 
or fusiform cells having two, three or four short 
unbranched processes and multiple nuclei (Fig. 18 and 
Table 2, Section I.4.4.I.). In most passages, the most 
frequent cell type was the spindle-shaped cell. THe 
round and bipolar cells were sometimes difficult to 
distinguish from the other cell types, suggesting that 
these may be different forms of the same cell. TE671 
cells exhibited independent cell growth on either a 
solid substrate (in 80cm3 flasks, in continuous culture) 
or chemical substrate (polylysine coated culture plates) 
and were not contact inhibited, continuing to grow over 
an already established cell monolayer.
3.2.2. Characterisation of TE671 cell AChR.
3.2.2 .1. AChR content of intact and solubilised TE671 
cells.
The extents of [125I] a-BGT binding to intact cells 
and to those cells solubilised with the non-ionic 
detergent, Triton X-100 are shown in Table 6. As cells 
are known to be impermeable to a-BGT (Kemp and Edge, 
1987), incubation in the absence of detergents would be
109











Table 6. [125I] a-BGT binding to intact and
solubilised TE671 cells.
Binding was determined as previously described 
(Section 2.11.3.2.), using the cholinergic antagonists 
d-tubocurarine (l.OmM) or a-BGT (l.OyM) to determine 
non-specific binding.
Results are mean + /- SEM (n=3), with the assay 




[125i] a-BGT binding to intact and 
solubilised TE671 cells.
AChR (pmol/mg protein 
Intact Solubilised
d-TC 30.85 ± 5.99 52.05 + 10.63
a-BGT 26.21 ± 1.90 47.71 ± 4.49
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expected to saturate only cell surface sites. If 
additional sites are present, then solubilisation of the 
cells with detergent would result in their being 
detected. The approximately two-fold increase in a-BGT 
binding sites observed on solubilisation suggests that a 
significant fraction of the a-BGT binding sites on TE671 
cells are intracellular.
3. 2 . 2 . 2 . Properties of [125I] a-BGT binding to TE671 
cells.
[ a.2 s i ] a-BGT bound to a single saturable high 
affinity site on intact TE671 cells as indicated by 
linear Scatchard plots (Fig. 19).
The Kd for binding to intact cells (mean + SEM (n)) 
was 2.03 ± 0.41nM (5). The Bmax was calculated (mean ±
SEM (n)) as 24.13 ± 3.70 fmol/mg protein (5).
3.2.2.3 . Apparent constants for inhibition, by 
cholinergic ligands, of [125I] a-BGT binding 
to TE671 cells.
Competition binding assays using cholinergic 
ligands to inhibit high affinity E12 51 3 a-BGT binding to 
TE671 cells were carried out as described (Section
2.11.3.4.). Dose response curves were generated (Figs. 
20 and 21) from which it can be seen that the
antagonist a-BGT was the most potent inhibitor of [125I] 
a-BGT binding (Tables 7 and 8), being two orders of
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Fig. 19. Binding of [1251 ] a-BGT to TE671 cells.
The binding of [125I] a-BGT to triplicate culture 
wells of confluent TE671 cells was determined as 
described (Section 2.11.3.3.).
Binding data are from 1 representative experiment 
showing:
( O ) Binding in the absence of d-tubocurarine 
chloride (total binding).
( • ) Binding in the presence of d-tubocurarine 
chloride (non-specific binding).
(A) Specific binding.


















Binding of [125I]<*-BGT to TE671 cells in culture.
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Fig# 20. Competition binding assays with
cholinergic antagonists for [125I] a-BGT 
binding to TE671 cells.
Competition assays as described in Section
2.11.3.4., for [ a. 2 51 ] a-BGT binding to TE671 cells were 
carried out in the presence of a-BGT ( a  ) f d- 
tubocurarine ( • ), decamethonium (±), benzoquinonium (o) 
and MLA (■). Results with the exception of a-BGT are 
the mean ± of 3 experiments, with each ligand 
concentration assayed in triplicate.
Table 7. Inhibition of [125I] a-BGT binding to 
TE671 cells by cholinergic antagonists.
Competition assays were performed as described 
(Section 2.11.3.4.), using [125I] a-BGT at 2.0nM. IC50 
values were derived from linear transformations of dose- 
response curves; Ki values were derived from IC50 values 
(Cheng and Prusoff, 1973), assuming Kd values for 
[12 51 ] a-BGT binding to TE671 cells of 2.0nM. Data are 
the mean of 2 or 3 of three independent determinations, 










FIG. 20 Competition binding assays with cholinergic antagonists for 





Table 7. Inhibition of t12 51 ] a-BGT binding to TE671 
cells by cholinergic antagonists.
a-BGT ( a ) d-TC (•) BZQ ( O )  MLA (■) DBr (a ) 
IC50 1. 3x10 - 9M 1. 9x10" 7M 2.5xlO-6M 1.0x10-<M 2.8x10-?M 
Ki 6.5x10“ 1 °M 9.8x10"8M 1.3xlO-6M 5.0x10-sm 1.4x10-?M
nH 1.21 0.60 0.88 0.87 0.76
r2 0.99 0.98 0.99 0.98 0.98
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Fig, 21• Competition assays with cholinergic
agonists for [125I] a-BGT binding to TE671 
cells.
Competition assays as described in Section
2.11.3.4., for [125I] a-BGT binding to TE671 cells were
carried out in the presence of:
a) (-)-Nicotine (O) and acetylcholine (a).
b) Carbamylcholine (•) and ( + )-nicotine (■).
Results are the mean ± SEM of three experiments, or 
the mean of two experiments (carbamylcholine), with each 
ligand concentration assayed in triplicate.
Table 8. Inhibition of 112 51 ] a-BGT binding to
TE671 cells by cholinergic agonists.
Competition assays were performed as described 
(Section 2.11.3.4.) using [ 12 51 1 a-BGT at 2.0nM. IC50
values were derived from linear transformations of the 
dose response curves; Ki values were derived from IC50 
values (Cheng and Prusoff, 1973), assuming Kd values for 
[ 12 si ] a-BGT binding to TE671 cells of 2.0nM. Data are 
the means of at least three independent determinations, 
carried out in triplicate.
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FIG. 21 Competition binding assays with cholinergic agonists for [ ‘“ |]«BGT 
binding to TE671 cells.
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0
7 -6  -5  -4  -3
100
7 - 6  -5  -4
Table 8. Inhibition of l125I] a-BGT binding to TE671 
cells by cholinergic agonists.
(-)Nic ( O )  (+)Nic (■) ACh ( a ) Carb (•)
IC50 2 . 6x10-6M 4.9x10“6M 3 . 4xl0-7M 1. 7x10"6M
Ki 1. 3x10~ 6M 2 . 4x10-6M 1. 7x10-7M 8.7x10"7M
ne 0.59 0.59 0.85 0.61
r 2 0.99 0.98 0.97 0.98
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magnitude more potent than d-tubocurarine,
decamethonium, benzoquinonium, the stereoisomers of 
nicotine and carbamylcholine. Methyllycaconitine (MLA) 
showed the lowest potency in these studies. The lack of 
effect of MLA was further investigated in the same assay 
but using frog muscle and human muscle preparations
(Section 2.11.3.5.). From the results shown in fig. 22 
and Table 9, it can be seen that MLA showed slightly
higher potency in competing for high affinity [12 51 ] a- 
BGT binding compared with that in TE671 cells. These
results contrast to its very potent effect in rat brain
P2 membranes prepared as described (Section 2.5.). Other 
ligands, choline, hexaraethonium, atropine, glutamine and 
glycine were also tested, but were without effect.
3.2.3. Inhibition of [125I] a-BGT binding to TE671 cells 
by myasthenic serum.
Serum samples from 3 patients with myasthenia 
gravis were tested for their ability to inhibit high 
affinity [ 12 51 ] a-BGT binding to intact TE671 cells as 
previously described (Section 2.11.3.6.). The sera 
tested varied in their anti-AChR antibody titres as 
determined by radioimmunoassay (Section 2.6.). Hill 
plots were generated for each serum tested (Fig. 23) and 
IC50 values were obtained from them (Table 10). The 
results show a correlation between decreasing anti-AChR 
antibody titre and decreasing IC50 value.
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Fig. 22. Competition binding assays with MLA for 
[12 5 1 ] a-BGT binding to various tissues.
Competition binding assays for [125I] a-BGT binding 
to frog muscle extract (•), human muscle extract (O) 
and rat brain P2 membranes (□) were carried out in the 
presence of MLA (Section 2.11.3.5.). Results are the 
mean ± of 3 determinations (frog and rat brain P2 
membranes) or 5 determinations (human), with each ligand 
concentration assayed in triplicate.
Table 9. Inhibition of [12 51 ] a-BGT binding to 
various tissue preparations by MLA.
Competition assays were performed as described 
(Section 2.11.3.5.), using [ 1 2 51 ] a-BGT at 2.0nM. IC50 
values were derived from linear transformations of dose- 
response curves; Ki values were derived from IC50 values 
(Cheng and Prusoff, 1973), assuming Kd values of l.OnM 
for a-BGT binding to both tissues. Data are the mean of 











FIG. 22 Competition binding assays with MLA for [ 125l] <*-BGT binding to 
various tissues.
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Table 9. Inhibition of [12 51 ] a-BGT binding to various 
tissues by MLA.
i
Frog (•) Human (o) Rat brain (□)
IC50 2.4x10-6M 2.9xlO_5M 2.2xlO-9M
Ki 1.2xlO_6M 1.4x10"5M l.lxlO-*M
nH 0.60 0.63 0.75
r2 0.93 0.98 0.76
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Fig. 23. Inhibition of [125I] a-BGT binding to 
TE671 cells by myasthenic serum.
High affinity [125I] a-BGT binding to intact TE671 
cells was inhibited following exposure of the cells to 
increasing concentrations of myasthenic serum samples 
(Section 2.11.3.6.).
Results are expressed as a percentage of binding in 
the presence of normal human serum (control binding) 
which was without effect.
The results shown are either the mean ± SEM of 3 














FIG. 23 Inhibition of [ IZ5 I] c*-BGT binding to TE671 cells by
myasthenic sera.
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Table 10 Summary of results obtained from
inhibition of [125I] a-BGT binding by 
myasthenic sera.
Anti-AChR antibody IC50 value (antiserum dilution) 





3.2.4. TE671 CELLS? CYTOTOXICITY STUDIES.
3 . 2 . 4.1. Lactate dehydrogenase [EC 1.1.1.27] in TE671 
cells.
TE671 cells were harvested as previously described 
(Section 2.11.2.). The presence of LDH was detected by 
using a colorimetric assay based on that described by 
Bergmeyer and Bernt (1974) (for details, see Section
2.11.4.2.).
Triton lysis of TE671 cells demonstrated high 
levels of LDH as monitored by an increase in optical 
density at 492nm. The optical density at 492nm for 
seeding 5000 - 10000 cells/lOOyl/well was in the range
1.399 ± 0.028 - 2.478 + 0.033 (mean ± SEM (n=8)). All
subsequent experiments were carried out at seeding 
densities that resulted in cell numbers within this 
range at the time of assay.
3.2.4.2. Cytotoxic effects of serum and GPC on TE671 
cells: Preliminary investigation.
TE671 cells were harvested, resuspended in HBSS and 
plated out into each well of a 96 well plate as 
previously described (Section 2.11.2.).
These cells were incubated, in quadruplicate, with 
heat-inactivated normal human serum samples or a 
myasthenic serum sample (lOyl, 10% v/v) in the presence 
or absence of GPC (lOyl, 10% v/v) for 3h at 37#C in an
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atmosphere of 10% C02/air.
Cytotoxicity of serum with or without GPC was
calculated as a percentage of LDH released from these
cells with respect to LDH released from the same cells 
lysed with Triton X-100 as previously described 
(Section 2.11.4.2.).
Using the conditions described above, heat
inactivated serum, both normal and myasthenic, with or 
without GPC, gave similar values of cytotoxicity (Table 
11). This led to a further investigation of a larger 
pool of samples.
3 .2 .4.3. Extended study.
TE671 cells in 96 well plates were set up as 
described above (Section 3.2.4.2«). The effects of six 
heat inactivated normal human serum samples, a pooled 
normal human serum sample and four myasthenic serum 
samples (lOyl, 10% v/v) were investigated on
quadruplicate cultures in the presence or absence of GPC 
(lOyl, 10% v/v). After incubation for 3h at 37#C in an 
atmosphere of 10% CC>2 /air, cytotoxicity measured by 
release of LDH was calculated as previously described 
(Section 2.11.4.2.).
Heat inactivated normal human serum samples in the 
absence of GPC showed cytotoxicity values within the 
range 28-40% (mean 34%), in the presence of GPC, 
cytotoxicity values were very similar, within the range 
30-41% (mean 36%). Heat inactivated myasthenic serum
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Table 11. Cytotoxicity of serum and complement on 
TE671 cells as monitored by release of
cytosolic LDH.
TE671 cells in a 96 well plate were exposed to
samples of test serum (lOyl, 10% v/v) in the presence 
or absence of GPC (lOyl, 10% v/v) for 3h at 37#C.
Control cultures to which no additions were made and
those to which GPC alone was added were run
simultaneously. At the end of the incubation period, the 
cultures were tested for release of cytosolic LDH as
described (Section 2.11.4.2.) as a percentage of LDH
released from cells lysed with Triton X-100. Each serum
sample was added to quadruplicate culture wells.
Table 11. Cytotoxicity of serum and complement on TE671 
cells, monitored by release of cytosolic 
LDH.
Treatment Anti-AChR Optical Density LDH Released
Ab titre 490nm + (SEM) % Triton lysed 
(nM) (n=4) cells
(cytotoxicity)
Triton-lysed - 2.27+0.42 100
HBSS no cells - 0.00 0
HBSS with cells - 0.097+0.008 4
NHS (1) - 0.641+0.037 28
NHS (1) + GPC - 0.661+0.031 29
NHS (2) - 0.738+0.032 34
NHS (2) + GPC - 0.806+0.029 35
MG1 42.00 0.701+0.054 31
MGl +GPC 42.00 0.785+0.062 34
GPC _ 0.397+0.028 17
NHS = Normal human serum 
MG = Myasthenia gravis serum 
GPC = Guinea pig complement
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samples showed cytotoxicity values essentially no 
different to those observed with normal human serum; 
values within the range 25-38% (mean 31%) in the 
absence of GPC and 27-38% (mean 33%) in the presence of 
GPC (Fig. 24), indicating a lack of discrimination 
between the groups of serum samples under these 
conditions.
3.2.4.4. Titration of serum.
Quadruplicate cultures of TE671 cells in 96 well 
plates were set up as previously described (Section
2.11.2.). The effects of increasing concentrations of 
four different heat inactivated myasthenic serum samples 
(0 - lOyl, 0 - 10% v/v) were tested in the presence or 
absence of a fixed concentration of GPC (lOyl, 10% v/v). 
A heat inactivated pooled normal human serum was tested 
under the same conditions in parallel experiments. 
Cytotoxicity, measured by release of LDH was calculated 
as previously described (Section 2.11.4.2.).
The results demonstrate an increase in cytotoxicity 
as the concentration of serum increased in both the 
myasthenic serum samples and the pooled normal human 
serum from the corresponding experiment (Fig. 25a and
b) . This effect was mimicked in the presence of 
complement (Fig. 25c and d ) . Whilst the results showed 
variations between individual experiments (Fig. 25a,b,c 
and d), there was little difference in the values of 
cytotoxicity between pooled normal human serum and
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Fig. 24. Cytotoxicity of serum and complement on 
TE671 cells as monotored by release of 
cytosolic LDH.
TE671 cells in 96 well plates were exposed to 
samples of heat inactivated normal and myasthenic serum 
samples (lOyl, 10% v/v) in the presence (solid bars) or 
absence (open bars) of GPC (lOyl, 10% v/v). Control
cultures to which no additions were made were included 
in the test.
Cytotoxicity was calculated as previously 
described. Results are the mean of two experiments.
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FIG. 24 Cytotoxicity of serum and complement on TE671 cells as monitored by 
release of cytosolic LDH
100
50 -
normal human sera myasthenic serum
anti-AChR - - - - - - -  42 0 20 6 9 0 761
antibody titre  (nM)
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Fig. 25. Cytotoxic effect of increasing
concentration of normal or myasthenic 
sera, monitored by release of cytosolic 
LDH.
TE671 cells in 96 well plates were set up as 
previously described (Section 2.11.2.) and exposed to 
pooled normal human serum or four different myasthenic 
sera (0 - lOyl, 0 - 10 % v/v) in the presence or absence 
of GPC (lOyl, 10% v/v). Cytotoxicity was calculated as
the percentage LDH released compared with cells lysed 
with Triton X-100 (Section 2.11.4.2.).
a) Increasing concentrations of normal human serum 
without GPC. ( □ ) ,  ( ■ ) ,  ( • ) ,  (o) and ( a )  corresponding MG 
patients (b).
b) Increasing concentrations of 4 myasthenic serum 
samples without GPC. ( O :MG3), ( ■ :MG9), ( □ :MG8) and (• 
:MGl).
c)Increasing concentrations of normal human serum in the 
presence of GPC. Symbol details as above ("a").
d)Increasing concentrations of 4 myasthenic serum 
samples in the presence of GPC. Symbol details as above 
("b").
d)Pooled results of increasing concentrations of normal 
human serum in the absence (O) or presence ( • ) of GPC. 
Results are the mean ± SEM, n=5.
f)Pooled results of 4 myasthenic patients in the absence 







FIG. 2S Cytotoxic e ffect of increasing concentration of normal or 
myasthenic sera, monitored by release of cytosolic LDH. 
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myasthenic serum in the presence or absence of GPC (Fig. 
25e and f). However, an increase in cytotoxicity in the 
presence of GPC was noticeable after the addition of lyl 
of serum in the test and control samples (Fig. 25e and 
f), this effect was further investigated (Section
3.2.4.6.).
As the myasthenic serum samples used in this study 
had been stored, frozen for a considerable period of 
time, a cytotoxic effect of fresh myasthenic serum 
samples was also investigated.
3 .2.4.5. Titration of fresh myasthenic serum.
Fresh serum samples from myasthenic patients were 
obtained from Southmead Hospital, Bristol, U.K.. In the 
case of large volumes of serum (>200ml), half of the 
serum was heat inactivated (56°C) and the remainder 
untreated. The serum was then stored, frozen, in 1ml and 
2ml samples. Samples were thawed as required for each 
experiment and any serum remaining was discarded.
Quadruplicate cultures of TE671 cells were set up 
as previously described (Section 2.11.2.). Fresh 
myasthenic serum samples were titrated as described 
above (0-10yl, 0-10% v/v) in the presence or absence of
a fixed concentration of GPC (lOyl, 10% v/v),
cytotoxicity was measured by release of LDH as
previously described (Section 3.2.4.2.).
An initial experiment (Fig. 26a) indicated a
poosible cytotoxic effect of a particular myasthenic
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serum in the presence of complement, cytotoxicity <40% 
for serum without complement and >50% in the presence of 
complement. Subsequent experiments using the same serum 
sample under identical conditions were not able to 
reproduce this result (Fig. 26b). A different myasthenic 
serum sample (Fig. 26c) also failed to show an obvious 
effect of complement-mediated cytotoxicity.
3 . 2.4 .6. Reduced titration range.
From previous experiments, it was noted that 
complement mediated cytotoxicity was most marked at a 
low added concentration of serum (lyl, 1% v/v, see "Fig. 
25e and f"). This effect was further investigated.
Quadruplicate cultures of TE671 cells were set up 
as previously described (Section 2.11.2.). The cultures 
were incubated with fresh or stored heat inactivated 
myasthenic serum samples (0-4yl, 0-4% v/v) in the
presence or absence of GPC (lOyl, 10% v/v) for 3h at 
37°C, cytotoxicity was calculated as previously 
described (Section 2.11.4.2.).
Complement-mediated cytotoxicity was more apparent 
using fresh serum (Fig. 27a) than with stored serum 
(Fig. 27b), again at the lower added concentrations of 
serum. However, such an effect was not consistent over 
the titration range.
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Fig. 26. Cytotoxic effect of fresh myasthenic sera 
and complement on TE671 cells, monitored 
by release of cytosolic LDH.
TE671 cells in 96 well plates (Section 2.11.2.) 
were exposed to fresh myasthenic serum (0 -lOyl, 0 - 10% 
v/v) in the presence (■) or absence (□) of GPC (lOyl, 
10% v/v). Cytotoxicity was calculated as previously 
described•
a) Single representative experiment using a myasthenic 
serum sample (MG10). Each point is the mean of 
quadruplicate culture wells.
b)Pooled results of a myasthenic serum (MG10). Results 
are the mean ± SEM 5 individual experiments.
c)Pooled results of a myasthenic serum (MG11). Results 
are the mean ± SEM 4 individual experiments.
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FIG- 26 Cytotoxic effect of fresh myasthenic sera and complement on 















Fig. 27. Cytotoxicity of fresh and stored
myasthenic serum and complement on TE671 
cells, monitored by the release of 
cytosolic LDH.
TE671 cells in 96 well plates (Section 2.11.2.) 
were exposed to fresh and stored heat inactivated 
myasthenic sera (0 - 4yl, 0 - 4 %  v/v) in the presence or 
absence of GPC (lOyl, 10% v/v). After incubation (3h, 
37°C) cytotoxicity was calculated as previously 
described (Section 2.11.4.2.).
a)Fresh myasthenic serum (MG9) without GPC ( a )  
fresh myasthenic serum (MG9) with GPC (a )
b ) Stored myasthenic serum (MG3) without GPC ( a )





FIG. 27 Cytotoxicity of fresh myasthenic serum and complement on 





3.2.4.7 . Heat inactivation of serum.
Quadruplicate cultures of TE671 cells were set up 
as previously described (Section 2.11.2.). Two fresh 
myasthenic samples (0-4yl, 0-4% v/v) which had been
heat inactivated immediately before storage or left 
untreated, were tested for cytotoxicity in the presence 
or absence of GPC (lOyl, 10% v/v) as previously 
described (Section 2.11.4.2.).
The results show that the abolition of endogenous 
complement in the serum by heat treatment (Fig. 28b and 
d) had no effect compared with serum that had not been 
heat inactivated (Fig. 28a and c).
3.2 .5 .1. Endogenous LDH in serum: detection.
TE671 cells have high levels of cytosolic LDH, as 
determined by lysis with Triton X-100 (Section
3.2.4.I.). However, specific complement-mediated lysis 
by myasthenic serum samples remained elusive. Although 
endogenous levels of LDH in the serum samples used in 
the assays were assumed to be too low to affect the 
cytotoxicity assay, these levels were checked 
carefully.
Quadruplicate samples of serum (0-10% v/v in HBSS, 
lOOyl) in 96 well plates, were assayed for the presence 
of LDH, as described for TE671 cells after lysis with 
Triton X-100 (Section 2.11.4.1.). Apart from purified
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Fig. 28. Effect of heat inactivation of myasthenic 
sera and complement on release of 
cytosolic LDH.
TE671 cells in 96 well plates (Section 2.11.2.) 
were exposed to increasing concentrations of two 
myasthenic serum samples (0 - 4yl, 0 - 4 %  v/v) in the
presence (*) or absence ( a ) of GPC (lOyl, 10% v/v). 
After incubation (3h, 37°C), cytotoxicity was calculated 
as previously described.
a)Myasthenic serum (MG12) non-heat inactivated
b)Myasthenic serum (MG12) heat inactivated
c)Myasthenic serum (MG13) non-heat inactivated
d)Myasthenic serum (MG13) heat inactivated
Results are from represntative experiments and are 
the mean of quadruplicate culture wells.
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FIG. 28 Effect of heat inactivation of myasthenic sera and complement 
















IgG fractions, all the serum samples showed LDH (Fig. 
29ab). However, the levels only represented 20-50% of 
the LDH that could be released by Triton X-100 (Section
3.2.4.1.).
3 . 2 . 5 . 2 . Endogenous LDH isoforms in serum: selective 
inhibition or removal.
LDH has several isoenzymes, the isoform 
predominating in blood is LDHl, although myasthenic 
serum samples may have some LDH5 as a result of damage 
at the muscle end-plate. The LDH isoenzymes can be 
differentiated by heat denaturation (Bergraeyer and 
Bernt, 1974). Serum samples were routinely heat 
inactivated (56°C, lh) and further heat treatment was 
thought to be unnecessary.
3.2.5 . 3 . Inhibition by oxalate.
LDHl can be selectively inhibited by 0.2mM oxalate. 
Quadruplicate serum samples (lOOyl, 0-10% v/v in HBSS 
containing 0.2mM oxalate, final concentration) were 
assayed for the presence of LDH as described above. 
Inclusion of oxalate in the assay buffer had little 
effect on inhibition of serum LDH levels with respect to 
serum samples in HBSS without oxalate (Fig. 30abc and
d) .
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3.2.5.4. Separation of isoforms on DEAE-Sephadex A-50.
The individual isoforms of LDH can also be 
separated from each other by chromatography. The most 
effective method for separating LDHl is by adsorption on 
DEAE-Sephadex•
DEAE-Sephadex A-50 was prepared and mixed with 
serum samples as previously described (Section 
2.11.4.3.). Samples treated with 0.2mM oxalate and 
subsequently adsorbed onto the matrix were also 
investigated. Samples of the resulting eluates were 
assayed for LDH activity as described above. Dilution of 
the serum after treatment with the matrix was taken into 
account. The effect of this treatment is shown in Fig. 
30 (a,b,c and d). Adsorption resulted in a 50-60% 
lowering of serum LDH levels in both normal and 
myasthenic serum samples with respect to untreated 
samples and those treated with 0.2mM oxalate. There was 
no apparent advantage afforded by 0.2mM oxalate in the 
HBSS or with its use in conjunction with DEAE-Sephadex 
A-50.
3.2.5.5. Removal of LDH on Matrex Blue-gel A.
An additional method considered for the removal of 
serum LDH was the use of Matrex Blue-gel A. This is a 
cross-linked 5% agarose covalently coupled to Cibacron 
Blue 3GA and specifically removes all NAD+-dependent 
enzymes.
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Fig. 29. Optical density (OD492) of sera used in
cytotoxicity assays, measurement of 
endogenous LDH.
Serum samples in HBSS (lOOyl, 0 - 10% v/v) were 
tested for LDH activity as described (Section
2.11.4.1.).
a)Increasing concentrations of:
(□)Pooled normal human serum
(■)GPC
(•)Normal human IgG 
(o)Myasthenic IgG (MGl)




(a )M G 3 
(•)MG6












FIG. 29 Optical density (0D 492nm) of sera used in cytotoxicity assays, 








0 5 10 %  Serum
148
Fig. 30. Optical density (OD492) of sera used in 
cytotoxicity assays after selective 
inhibition of LDH.
Serum samples in HBSS (lOOyl, 0 - 10% v/v) were
tested for LDH activity as previously described
(Section 2.11.4.1. ), after the following treatments: 
(•)0.2mM oxalate in HBSS 
(■)Adsorption onto Sephadex A-50
(□)Adsorption onto Sephadex A-50 andtreatment with 0.2mM
oxalate in HBSS 
(O)No treatment.
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Matrex Blue-gel A pretreated as described in 
Section 2.11.4.3.) and used to adsorbe serum LDH as 
described above (Section 3.2.5.4.). This treatment was 
no more effective in adsorbing the LDH than that using 
Sephadex A-50 (Fig. 31).
3.2 .5 .6 . Effects of adsorption on anti-AChR antibody
titre.
A potential problem of adsorbing sera onto either 
of the two matrices, Sephadex A-50 or Matrex Blue-gel A, 
is the concomraitant adsorption of myasthenic 
immunoglobulins. This would render a serum less useful 
for investigation of complement mediated lysis.
The standard radioimmunoassay for anti-AChR 
antibodies (Section 2.6.) was performed on untreated 
sera and on those adsorbed onto the matrices. The 
results are summarised in Table 12., where it can be 
seen that treatment with A-50 resulted in less 
antibodies being removed than with Blue-Gel.
3.2 . 5 .7 . Effect of adsorption on the cytotoxic effects
of serum and complement on TE671 cells.
A pretreated myasthenic serum (adsorbed onto either 
Blue-Gel or Sephadex) was tested for complement-mediated 
cytotoxicity, measured by the release of LDH as 
previously described (Section 2.11.4.2.). Using either
151
treatment, A-50 or Blue-Gel, there was no difference in 
levels of cytotoxicity in the presence or absence of GPC 
(Fig. 32a and b ).
3.2.6. Radiolabel.
3.2.6 .1. Uptake of L-[Me-3H] carnitine and [51Cr] by
TE671 cells.
TE671 cell cultures were tested for uptake of 
radioactivity after incubation with L-[Me3H] carnitine 
or [51Cr] as described (Section 2.11.5.). Figs. 33 and 
34 illustrate that uptake of radiolabel in both cases 
was not saturating over the concentration range tested 
(0 - lOyM carnitine; 0 - 0.2yCi chromium). Saturation 
with chromium was still unattainable after increasing 
the concentration from 0 - 20\iCi.
TE671 cells in culture are not contaminated by 
additional cell types that would reduce the specificity 
of a cytotoxicity assay system similar to that found 
with human myotube cultures (Section 1.11.1.). TE671 
cells also represent a continuous supply of material for 
assay. t51Cr] was chosen as the radioligand to help 
reduce the cost of the assay.
3.2.6 . 2 . Effect of washing on release of [51Cr] from
TE671 cells.
TE671 cells were labelled with [51Cr] (0-20yCi/wel1) by
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Fig. 31. Comparison of Sephadex A-50 and 
Matrex Blue-gel as methods for 
adsorption of serum LDH.
A myasthenic serum (MG12) in HBSS (lOOyl, 0 - 10% 
v/v) was adsorbed onto Sephadex A-50 (■), Matrex Blue- 
gel (□) or left untreated ( o ) and tested for LDH 
activity as previously described.





FIG. 31 Comparison of Sephadex A-50 and Matrex Blue-gel as methods 






Table 12. Effect of adsorption on anti-AChR antibody 
titre.
Anti-AChR antibody titre <nM)






NHS - - - - -
MG13 35.1 31.0 11.7 25.0 29.0
MG12 24.6 21.9 11.0 16.4 33.0
MG 3 71.3 69.2 3.0 _
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Fig. 32. Cytotoxicity of adsorbed serum and
complement on TE671 cells, monitored by 
release of cytosolic LDH.
TE671 cells in 96 well plates (Section 2.11.2.) 
were exposed to an adsorbed myasthenic serum sample 
(MG12), (0 - lOyl, 0 - 10% v/v) in the presence ( • ) or 
absence (O) of GPC (lOyl, 10% v/v).
a)Serum adsorbed onto Sephadex A-50
b)Serum adsorbed onto Matrex Blue gel
Cytotoxicity was calculated as previously 
described. Results are the mean of quadruplicate culture 









FIG. 32 Cytotoxicity of adsorbed serum and complement on TE671 cells, 









Fig. 33. Uptake of L-[Me-3H] carnitine by TE671 
cells•
The uptake of radioactivity by TE671 cells in 
culture was determined after incubation with increasing 
concentrations of L-[Me-3H] carnitine for 18h at 37°C 
as described in Section 2.11.5.. Results are from 1 
representative experiment, each concentration is the 























Fig. 34. Uptake of [slCr] by TE671 cells in 
culture.
The uptake of radio activity by TE671 cells in 
culture was determined after incubation with increasing 
concentrations of l51Cr] for 18h at 37°C as described in 
Section 2.11.5.. Results are from 1 representative 


















FIG. 34 Uptake of [ 51Cr] by TE671 cells in culture.
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incubation for 18h at 37°C (Section 2.11.5.). Cells were 
then washed, fresh medium (0.5ml) was added and the 
cultures were further incubated (37#C, 3h). After this 
time, replicate culture wells were washed and their 
contents were solubilised and counted for radioactivity. 
Fig. 35 shows the amount of radioactivity lost from the 
cells to the medium and that retained within the cells 
before and after washing. Loss of radioactivity was 
minimal and essentially linear with [51Cr] content 
release being no higher than 9% in the incubation period 
( 3%/h) .
3.2.6.3 . Effects of lytic agents on [51Cr1 labelled
TE671 cells.
After labelling with [51Cr] (2.5yCi/wel1, 18h,
37#C; Section 2.11.5.). TE671 cell cultures were washed 
and the effects of Triton X-100 and distilled water were 
tested. Fig. 36 illustrates that lysis could be effected 
by concentrations above and including 0.05% (v/v) Triton 
X-100 and by distilled water alone. Higher added 
concentrations of Triton X-100 were tested (0.25-1.0% 
v/v), these concentrations effected detachment of cells 
from the culture plates.
3.2.6.4 . Cytotoxicity of serum on t51Cr] labelled TE671
cells: Titration of serum.
A cytotoxicity assay based on the L-[Me-3H]
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Fig. 35. Effect of washing on release of [51Cr] from 
TE671 cells.
Quadruplicate wells were labelled with increasing 
concentrations of [51Cr] as described in Section
2.11.5.. The cultures were washed and fresh growth 
medium containing no radiolabel was added. The retention 
of radioactivity in the cells after a 3h incubation
period at 37°C without washing (□) and after 3 washes
( ■ ) was determined. The medium above the cells was 
removed for counting as an indication of radioactivity 
released ( a ) results are from two independent
experiments.
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Fig. 36. Effects of lytic agents on [51Cr] 
labelled TE671 cells.
TE671 cells were labelled with [51Cr] (2.5yCi/wel1) 
for 18h at 37"C. Lysis was effected by addition of 
fresh medium containing Triton X-100 or double distilled 
water for 30 minf 37#C. Medium above the cells (hatched 
bars) was removed and counted for radioactivity. The 
cells remaining were washed, extracted and counted for 
radioactivity (open bars) as previously described 
(Section 2.11.5.).
Results are from two resentative experiments.
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FIG. 36 Effects of lytic agents on [ 51Cr] labelled TE671 cells.
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carnitine assay monitoring the myotoxicity of serum and 
GPC on cultured human myotubes (Section 2.10.4.), was 
used to investigate similar effects on TE671 cells 
labelled with I51Crl.
The effects of increasing concentrations of heat- 
inactivated myasthenic serum and a pooled normal human 
serum (0-100% v/v and 0-90% v/v respectively) were 
tested on quadruplicate cultures of [51Cr] labelled 
TE671 cells in 24 well plates. From Fig. 37 it can be 
seen that cytotoxicity was a function of the amount of 
serum added. In the case of normal human serum, addition 
at concentrations greater than 70% (v/v) resulted in 
detachment of cells from the culture plate.
3 .2 .6 .5 . Effect of serum and GPC.
TE671 cell cultures labelled with [51Cr] in 24 well 
plates as described above, were incubated with 
increasing concentrations of heat-inactivated serum (0- 
100% v/v) in the presence of a constant concentration of 
GPC (150yl). Under these conditions a cytotoxic effect 
of myasthenic serum and GPC was most marked at 10-20% 
(v/v) myasthenic serum (Fig. 38). A value of 20% (v/v) 
serum was chosen for the subsequent cytotoxicity 
studies.
3 . 2 .6 .6. Effect of anti-AChR antiserum-
An antiserum which was raised against the fetal
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Fig. 37. Cytotoxicity of serum on [51Cr] labelled 
TE671 cells.
TE671 cells were labelled with [51Cr] as previously 
described. Increasing volumes of heat inactivated normal 
(■) or myasthenic serum samples (□), (0 - 100% v/v) were
added and cultures were incubated for 3h at 37"C. 
Control cultures to which no additions of serum were 
made were run simultaneously.
At the end of the incubation period, the cultures 
were washed and extracted for counting. Cytotoxicity was 
calculated as described in Section 2.11.5.1.. Each 
addition was tested on 4 culture wells in duplicate.
* *













Fig. 38. Cytotoxicity of serum and complement on 
I51Cr] labelled TE671 cells.
TE671 cells were labelled by incubation with [51Cr]
(2.5yCi/wel1 as previously described (Section 2.11.5.). 
Increasing volumes of heat inactivated normal ( ■ ) or 
myasthenic serum ( □ ), followed by the addition of a 
fixed volume of GPC (150yl) were added and cultures 
were incubated for 3h at 37°C. Control cultures to which 
no additions of serum were made were included in the 
test.
At the end of the incubation period, the cultures 
were washed, solubilised and counted for radioactivity. 
Cytotoxicity was calculated as previously described 
(Section 2.11.5.1.). Each addition was tested on 
quadruplicate culture wells. Results are the mean ± SEM 








Cytotoxicity of serum and complement on [ 51 Cr] labelled 
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calf AChR by Ms. S. Walsh of this Department by repeated 
immunisations with small quantities of purified protein, 
was tested for complement-mediated cytotoxicity towards 
TE671 cell cultures by using the experimental conditions 
previously described (Section 2.11.5.1.). Under these 
conditions, the antiserum was shown to cross-react with 
the AChR on TE671 cells (Fig. 39) and the response was 
comparable to that seen with myasthenic serum (Fig. 38).
3.2.6.7 . Cytotoxicity of serum and GPC.
Quadruplicate cultures of TE671 cells labelled with 
[51Cr] were tested with heat-inactivated serum (20% v/v) 
in the presence or absence of GPC (as previously 
described for human muscle cell cultures labelled with 
L-[Me-3H] carnitine, Section 2.10.4.). Control cultures 
to which no additions were made (medium alone) were run 
simultaneously, within each experiment the effect of GPC 
added alone (150yl) was tested. Cytotoxicity was
calculated as previously described.
Under these conditions, the complement-mediated 
cytotoxicity of serum samples from 6 myasthenic patients 
and a pooled normal human serum were tested (Table 13 
and Fig. 40). Heat-inactivated serum, in the presence or 
absence of GPC showed wide variation among the treatment 
regimes, a specific complement-mediated effect of
myasthenic serum was not apparent.
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Fig. 39. Effect of anti-AChR antiserum on 
cytotoxicity of TE671 cells labelled with 
[5 xCr ]•
TE671 cells were labelled with [51Cr] as previously 
described (Section 2.11.5.). Increasing volumes of anti- 
AChR antiserum (rabbit anti-(fetal calf AChR) (0 - 50% 
v/v) in the presence (■) or absence (□) of GPC (150yl) 
were added and cultures were incubated for 3h at 378C. 
Control cultures to which no additions of serum were 
made were included in the test.
At the end of the incubation period, cultures were 
washed, solubilised and counted for radioactivity. 
Cytotoxicity was calculated as previously described.
Each addition was tested on quadruplicate culture 









FIG. 39 Cytotoxicity of anti-AChR antiserum on [ s1Cr] labelled
TE671 cells.
m "
50 %  Antiserum
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Table 13. Cytotoxicity of serum and complement on 
[51Cr] labelled TE671 cells.
TE671 cells were labelled by incubation with [51Cr] 
(2.5yCi/wel1)• The cells were then exposed to samples of 
myasthenic sera (20% v/v) in the presence or absence of 
GPC (150^1). Control cultures to which normal human 
serum was added (in the presence or absence of GPC) and 
to which GpC alone was added were included in each 
experiment.
Cytotoxicity was calculated as previously 
described. Results are the mean of 2 or the mean ± SEM 
of 4 - 9 independent experiments.
Fig. 40. Cytotoxicity of myasthenic serum and 
complement on [51Cr] labelled TE671 
cells•
Pictorial representation of the data presented in 
Table 13.
Where: 1 = MG2 NHS = Normal human serum
2 = MG1 MGS = Myasthenia gravis serum
3 = MG6 GPC = Guinea pig complement




T a b l e  1 3 .  C y t o t o x i c i t y  o f  s e r u m  a n d  c o m p l e m e n t  o n  l 5 1 C r ]  
l a b e l l e d  T E 6 7 1  c e l l s .
P a t i e n t MG 2 M G 1 MG 6 MG 3 M G 1 2 M G 1 4
T i t r e ( n M ) 2 0 . 6 0 4 2 . 0 0 9 . 0 0 7 1 . 3 0 2 4 . 6 0 5 4 . 0 0
T r e a t m e n t ( n = 8 ) ( n = 9 ) ( n  = 4  ) ( n =  2 ) ( n = 2 ) ( n = 2 )
N H S - 1 . 7 5
± 5 . 8 1
- 7 . 2
± 6 . 2 0
- 1 3 . 2 5
± 2 . 4 0
- 0 . 5 4 . 0 - 1 0 . 0
N H S  + G P C 1 . 1 3
± 4 . 6 0
- 2 . 7 8
± 5 . 7 5
- 5 . 2 5
± 5 . 9 0
4 . 0 5 . 5 0 - 1 1 . 0
M G S 0 . 3 8
± 5 . 6 0
4 . 5 0
± 5 . 4 0
1 . 7 5  
± 5 .  9 0
- 1 . 5 0 1 0 . 0 1 . 5
M G S  + G P C 1 0 . 0
± 3 . 8 0
- 0 . 6 7
± 5 . 7 0
- 3 . 2 5
± 7 . 8 1
1 . 5 0 2 . 5 0 - 8 . 0
G P C 1 . 6 3
± 3 . 7 0
- 5 . 2 0
± 3 . 0
- 2 . 5 0
± 5 . 4 0
3 . 0 9 . 5 0 0 . 0
N H S  = N o r m a l  h u m a n  s e r u m  
M G S  = M y a s t h e n i a  g r a v i s  s e r u m  
G P C  = G u i n e a  p i g  c o m p l e m e n t







3.3.1. C3d degradation products: immunoselection.
The quantitation of complement, particularly C3 and
C4, provides useful evidence for the presence of
circulating immune complexes. One approach to assess 
complement consumption is the measurement of C3d, a 
relatively stable fragment of C3 produced during C3 
cleavage. C3d can be separated from the other fragments 
by its faster electrophoretic mobility or by
immunoselection with antisera of well defined 
specificity (Section 2.9.).
The standard design for C3d quantitations by
double-decker rocket immunoelectrophoresis is shown in 
Fig. 41 (abc and d ) , where it can be seen that a
specific anti-C3c antibody allows the free 
electrophoretic migration of C3d into a specific anti- 
C3d containing gel, while precipitating C3, C3b and C3c. 
In all cases (Fig. 41 abc and d) a standard dilution 
curve is demonstrated with the C3d preparation (for 
details, see "Fig. 41 legend”). A dose response curve in 
the form of smaller, sharply delineated rockets are also 
seen in the anti-C3c containing gel. These precipitates 
are formed by breakdown products from C3 with C3b and 
C3c specificities. Rockets in the same position (in the 
B gel) are also seen when plasma samples from patients 
or control plasma are examined. The rocket height tends 
to be greater for patient plasma samples. In Fig. 41 
(b), protein smearing was seen in the myasthenic patient 
EDTA-plasma samples, subsequent assays (Fig. 41 c and
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Fig. 41. C3 degradation products: immunoselection.
The design of the standard double-decker 
immunoelectrophoresis (DD RIE) for the quantitation of 
C3d was prepared as previously described (Section 2.9.). 
Gels A and C are native (antibody free) gel, gel B 
contains anti-C3c antibody and gel D contains anti-C3d 
antibody.
a)Wells 1 - 7 received dilutions of a standard C3d
preparation.
b) Wells 6 - 11 received dilutions of a standard C3d
preparation.







FIG. 41 C3 Degradation products ; Immunoselection
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c)Wells 8 - 1 3  received dilutions of a standard C3d 
preparation.









d) Wells 16 - 20 received dilutions of a standard C3d
preparation.
Wells 9 - 15 received EDTA plasma from patients with MG









Wells 7 and 8 received EDTA p;asma from two patients 
with classical rheumatoid arthritis.
Well 6 received EDTA negative control.
Agarose in Fig. "c and d" contained additionally 
1% w/v PEG 6000.
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d), employed 1% (w/v) PEG in the agarose gel to help 
reduce this and to improve the delineation of the 
protein peaks. When the heights of the C3d peaks are 
examined, they reveal elevated levels of C3d in all 
myasthenic patients tested as compared with negative 




The basic defect in MG is a reduction of AChRs at 
the neuromuscular junction and it is well established 
that the neuromuscular abnormalities are brought about 
by antibody-mediated processes. A great deal has been 
learned about the autoantibodies against AChRs and the 
pathogenetic mechanisms by which they produce their
effects at the neuromuscular junction in MG (for
reviews, see Vincent, 1980; Harrison and Behan, 1986). 
However, the relationship between circulating antibodies 
to AChR and the severity of the disease process in 
myasthenic patients is highly complex. The 
autoantibodies are heterogeneous and differ in their 
ability to induce the clinical and pathophysiological 
features of MG (Drachman et ad., 1987). The poor
correlation of the absolute serum antibody level with 
the clinical severity in MG may in part be explained by:
i) A proportion of the antibodies that are bound to 
AChRs at neuromuscular junctions, and thus do not enter 
the serum antibody pool.
ii) The serum antibodies may not be accurately
measured due to limitations of the radioimmunoassay.
iii) Variations in the concentrations of the IgG 
subclasses of antibody to AChR.
Determination of anti-AChR IgG subclasses is also 
relevant to the mechanism of cell destruction in post
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synaptic folds. Different IgG subclasses are involved in 
complement activation and in antibody-dependent cellular 
cytotoxicity (for review, see Natvig and Kunkel, 1973) 
which may play a role in MG.
4.1. Mechanisms for antibody loss.
Antigenic modulation is considered one of the two 
main mechanisms of AChR loss in MG. Antigenic modulation 
of the AChR has been analysed in tissue culture; where 
the potency of animal and human antisera on the AChR of 
animal tissue cultures was investigated (Heinemann et 
al ., 1977; Appel et al ., 1979; Conti-Tronconi et al ., 
1981; Drachman et al . , 1982; Hudgson et al. , 1982;
Tzartos et a_l. , 1985). AChR antibodies in these sera
were shown to cause a two- to three-fold enhancement of 
AChR internalisation. Attempts to correlate severity of 
disease and ability to cause antigenic modulation 
produced conflicting results (Conti-Tronconi et al ., 
1981; Drachman et al., 1982; Hudgson et al ., 1982). As
the sera were tested on animal cells, only those
antibodies able to cross react with the two AChR types
would be effective. This was proposed as a serious 
limitation of the technique, weakening the validity of 
the results. For further investigation it was suggested 
that human myotubes with surface AChR were required 
(Lennon et a l ., 1983).
There are relatively few reports of human fetal
muscle cells in culture, reflecting the difficulty in
184
supply. Most studies are based on the methods described 
by Yasin et ad. (1977) for the growth of dissociated 
adult human tissue.
However, Tzartos et al. (1986) realised the 
potential of the use of human tissue and used human 
muscle cell cultures to investigate antigenic 
modulation. The results showed that myasthenic sera 
could cause AChR loss from such cultures, but there was 
no correlation with clinical state or severity of the 
disease (Tzartos et al., 1986). They further suggested
that these cultures could be used to investigate other
effects of anti-AChR antibodies in MG, like the effect
of complement.
4.2. Human muscle cultures for investigation of
complement-mediated lysis.
In the present work, cultures of human muscle 
cells were established. Mononucleated cells settled on 
the collagen substratum and proliferated; the onset of 
fusion occuring spontaneously after 3-4 days in culture, 
aided by the reduction of serum supplement in the medium 
from 20-10%. The resulting myotubes continued to grow, 
forming a monolayer of slim cells with branching
extensions, interspersed with fibroblasts. Spontaneous 
contraction of the myotubes was observed in only one of 
the prepared cultures.
In order to quantify the myolytic effects of 
myasthenic serum and complement, use was made of a
185
quantitative assay for muscle cell lysis, originally 
developed by Cambridge and Stern (1981) to study 
myotoxicity in polymyositis. The method depends on the 
preferential uptake of L-[Me-3H] carnitine by cultured 
myotubes, loss of which can be monitored following 
cytolytic damage. A major advantage of this procedure 
was reported to be the very much slower uptake of 
carnitine by fibroblasts, which as mentioned earlier 
(Section 1.11.1.), contaminate myotube cultures 
(Cambridge and Stern, 1981).
In preliminary experiments, concentrations of 
myasthenic serum and GPC were used which had previously 
been shown to be myolytic to rat muscle cells in culture 
(Childs et ad., 1984, 1985, 1987). However, when such
conditions were applied to human muscle cells in 
culture, no significant lysis was obtained. It was found 
to be necessary to use at least a three-fold increase in 
concentrations of both myasthenic serum and GPC in order 
to demonstate lysis of the human muscle cells. Thus, 
Fig. 16 shows the results of increasing both myasthenic 
serum and GPC on myotoxicity, whereas increasing normal 
human serum and GPC had little effect.
The modified conditions were subsequently used to 
investigate a complement-mediated effect of five 
myasthenic serum samples. The results show that a 
combination of myasthenic serum and GPC gave higher 
levels of myotoxicity than the constituent components 
alone, or than normal human serum in the presence or 
absence of GPC (Fig. 17). It is not yet clear why such
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relatively high levels of both serum and GPC are needed 
to promote lysis in the human muscle cultures. The 
myotubes may be immature in culture, expressing 
different antigenic sites, such that sub-populations of 
antibodies, binding to the cultures, are less so 
effective at activating GPC. Adams and Bevan (1983,1985) 
showed that there is a sparse distribution of AChRs on 
human fetal muscle membranes, at a density of 1-4 
receptors per ym, which is considerably lower than the 
density on other preparations (Table 14).
If classical activation of complement is assumed to 
be involved in myolysis, Clq, the initial component of 
the complement cascade, must have two of its six binding 
sites (Fig. 42) bound to the antigen-antibody complexes 
to become stable. When IgG is bound to antigen, Clq 
binds to two separate IgG molecules via their Fc 
regions. However, the IgG molecules must lie within 30- 
40nm of each other as this is the maximum distance that 
Clq can span (Hughes-Jones et al., 1984; Burton, 1985). 
Dower and Segal (1981) showed that, in Clq binding to 
antibody coated cells, where antibody is bound to a 
membrane mobile antigen, Clq will bind preferentially to 
the region of highest antibody concentration. However, 
free IgG is a potent inhibitor of Clq binding when cell 
surface density of bound antibody is low. Therefore, 
free IgG might modulate Clq binding, preventing Clq 
fixation and activation on cells bearing low levels of 
antibody. This lends itself to a possible explanation 
for the difference in the myotoxic effects of myasthenic
187
Table 14. Density of AChR on cultured muscle 
cells.
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serum and GPC on rat and human muscle culture systems, 
with respect to the number and distribution of the 
surface antigen (AChR) available (Table 14).
However, once the antibody is bound to the antigen, 
the lytic phase of the complement pathway is initiated, 
culminating in the formation of the membrane attack 
complex (MAC). The assembly of the MAC may be divided 
into two stages with regard to function, structure and 
control (Podack, 1986).
1) The insertional event carried out by the 
trimolecular C5b-7 complex. This reaction proceeds 
without overt lysis but sets the stage for subsequent 
membrane damage (Fig. 43a).
2) Membrane damage by binding of C8 and the 
polymerisation of C9 to the tubular complex that is 
responsible for the ultrastructural membrane lesion 
(Fig. 43b) .
The formation of such a lesion in the membrane 
could cause an uncontrolled influx of extracellular 
ions, focal calcium excess (Campbell et a_l. , 1979), 
protease activation and disruption of the cytoskeletal 
elements within the post synaptic folds. Damaged 
segments bearing AChR, bound antibody and MAC may be 
shed into the synaptic cleft. The demonstration by Engel 
and Arahata (1987) of the MAC at all end plates in 7
cases of MG, reconfirms the effect of complement-
mediated injury of the post synaptic membrane in MG. 
Resealing of the membrane over the folds would then





'■ Scheme of assembly of the M AC and its control by S-protein. Metastable 
forms of C5b and C5b-7 are shaded tan. C5b is loosely bound to membrane C3b. In itia l 
attachment of the assembling M AC is via a transient binding site in C5b-7.
DJ. A  model of the M AC, in which C5b-8 directs polymerization o f poly 
C9 channels which traverse the cell membrane
Taken from Law and Reid (1988)
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folds and AChRs than the pre-existing one (Fig. 6).
It was found possible to demonstrate a complement- 
mediated lytic effect in the human muscle culture system 
using a limited number of myasthenic sera. However, more 
rigorous investigation using this system was made 
difficult by the sporadic availability of tissue of a 
suitable age and quantity and by the susceptibility of 
the cultures once established, to infection.
In order to further the investigation of 
complement-mediated lysis, an alternative and more 
consistent source of human tissue expressing AChR was 
sought•
4.3. TE671 human cell line.
The human medulloblastoma cell line, TE671, was 
chosen, as it had been reported to express an AChR that 
exhibits electrophysiological, immunological and 
pharmacological similarities to muscle. Other 
similarities to muscle, for example, the presence of 
muscle-associated enzymes were lacking until Stratton et 
al. (1989) noticed that TE671 cells had several of the 
phenotypic characteristics of striated muscle cells, 
including the presence of desmin and myoglobin. The 
amino acid sequences coded by the cDNA for both a and 6 
subunits of AChRs from TE671 cells show extensive 
homology with a and 6 subunits of AChRs from muscle 
(Schoepfer et ad., 1988), unequivocally demonstrating 
that AChRs from TE671 cells are of the "muscle-type".
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During the final stages of this project, it emerged, 
from DNA fingerprinting studies (Stratton et al., 1989;
Stratton, personal communication), that the TE671 cell
genotype was identical to that of a human
rhabdomyosarcoma cell line isolated from the same
laboratory as TE671 (McAllister et a^., 1969, 1977). 
Thus, the TE671 cell line may not be a medulloblastoma 
of neuronal origin, as originally thought, but does, in 
the light of this recent evidence, represent an even 
more suitable homogeneous population of human derived 
material for the study of human muscle AChRs.
Cultures of TE671 cells were successfully 
established. The cells in culture were anchorage 
independent, although a chemical substratum of 
polylysine was used in routine experimentation to help 
prevent cell detachment during the washing procedures. 
Once settled in culture, TE671 cells are polymorphic 
(Syapin et ad., 1982; Zeltzer et a^., 1984; Lukas, 
1986a); all cell types appear during all stages of 
culture growth. As the cells reach confluence, those 
cells with longer cellular extensions were blunted or 
lost in the massing efect. However, cells are not 
contact inhibited, continuing to grow over an already 
established monolayer.
The specific binding of [125I] a-BGT was 
demonstrated by the use of d-tubocurarine chloride, a 
cholinergic antagonist. Syapin et al.(1982) had 
previously demonstrated unusual potency of this drug in 
inhibiting [125I] a-BGT binding in these cells.
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Equilibrium binding studies, using [125I] a-BGT, 
indicated a high affinity binding site with a Kd of 
2.04nM, in agreement with the results of other workers 
(Table 15). Binding, with respect to the Bmax, was 
unaffected for up to three days in culture, in agreement 
with Lukas (1986a), who noted that once the cells 
achieve over confluence, the density of toxin binding 
sites per milligram of cellular protein decreases.
Approximately 50% of TE671 cell [12 51 3 a-BGT 
binding sites were found to be intracellular. There was 
no significant difference (students t-test) in the 
results when either a-BGT or d-tubocurarine were used to 
determine non-specific binding. Intracellular AChRs in 
muscle cells have been described. Fambrough and 
Devreotes (1978) reported 20-25% of AChRs on chick 
myotubes to be intracellular. Approximately half of 
these receptors were found to be associated with the 
Golgi apparatus and were inserted into the membrane in 
the presence of inhibitors of protein synthesis. They 
also found (Fambrough and Devreotes, 1978), that the 
remaining 50% of the intracellular receptors were 
associated with a "hidden" pool, that was not 
transported to the cell surface, and were degraded at 
the same rate as cell surface AChRs. Patrick et a l . 
(1977) had similar findings with the BC3H-1 cell line, 
as did Clementi et al. (1986) with the IMR32 human cell 
line. Kemp and Edge (1987) however, found that, of a 
similar intracellular pool of AChRs in PC12 cells, after 
treatment with cycloheximide, a small proportion were
194
Table 15. Toxin binding to TE671 cells.



















the immediate precursors of cell surface sites. Carlin 
et a l . (1986) found an intracellular precursor of mature
AChR in rat muscle cultures, by immunoprecipitation with 
monoclonal antibodies directed against the a subunit. 
This precursor bound a-BGT but was insensitive to the 
cholinergic ligands d-tubocurarine and decamethonium. 
Walker et al. (1988) had a similar finding with AChRs 
found in TE671 cell extracts. This was not found in this 
study but may reflect different growth stages of the 
TE671 cells with respect to the internal AChR 
population.
The role of such intracellular pools of cell 
surface proteins is not well understood. Intracellular 
pools of sodium channel a subunits have been identified 
in developing rat brain (Schmidt et slI. , 1985) and it 
has been suggested that the intracellular compartments 
may be involved in modulating rapid changes in cell 
surface receptor density.
The pharmacology of C12 51 3 a-BGT binding to TE671 
cells is consistant with a "muscle-type" of AChR. The 
most potent ligands inhibiting [12 51 ] a-BGT binding are 
the classical AChR antagonists a-BGT, d-tubocurarine and 
decamethonium; muscarinic and ganglionic AChR ligands 
showed little effect (Figs. 20 and 21). These results 
compare favorably with those of other workers (Table 
16) .
Displacement curves were analysed by Hill plots, 
where specific binding of radioligand in the absence of 
any displacing drug is taken as the Bmax and the binding
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Table 16. Inhibition of 112 51 1 a-BGT binding to TE671 




















































remaining at various concentrations of displacing drug 
is expressed as a percentage of Bmax. The Hill 
coefficients calculated from the slope of the lines 
should be unity if the displacement is of a competitive 
type and at a single set of binding sites. Hill 
coefficients below unity (and shallow displacement 
curves) indicate multiple binding sites in the 
interaction of two ligands. This may well be true of the 
stereoisomers of nicotine and of carbachol, as judged by 
their effects on binding of [125I] a-BGT to TE671 cells 
(Tables 7 and 8). d-Tubocurarine has been noted as 
having a shallow displacement curve in binding to TE671 
cells (Syapin et ad., 1982); displacement curves of a 
similar nature were not found in this study.
Methyllycaconitine (MLA), a naturally occuring 
toxin found in the seeds of Delphinium brownii, showed 
the lowest potency in inhibiting t125I] a-BGT binding to 
TE671 cells. Further investigations showed it to have 
similarly low potency in inhibiting toxin binding to 
frog and human muscle preparations; Hill coefficients 
for these preparations were lower than for those found 
in TE671 cells (Fig. 22 and Table 9) probably as a 
consequence of proteolysis.
MLA is a potent insecticide (Jennings et al., 1986) 
and moderately effective as an antagonist of the AChR at 
the neuromuscular junction in the rat phrenic nerve 
diaphragm preparation (Nambi-Aiyar et ad., 1979). 
MacAllan et ad. (1988) found it to be a potent inhibitor 
of [125I] a-BGT binding to rat brain (confirmed in this
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study (Fig. 22 and Table 9)) and to locust ganglia but 
a poor inhibitor of binding to Torpedo AChR. These data 
suggest that MLA displays a higher affinity for the a- 
BGT binding site found in neuronal tissue than that 
found at the periphery (Table 17) and may be useful as a 
prefential probe for the neuronal toxin receptor of 
vertebrates and invertebrates. These results further 
confirm the similarities between TE671 AChR and that of 
muscle.
The inhibition of [125I] a-BGT binding sites on 
TE671 cells by myasthenic serum was measured by 
determining the percentage of sites remaining after pre­
incubation of the cells with myasthenic serum. 
Reductions, relative to normal serum controls were shown 
in the three patients tested. These effects were 
independent of complement as the sera were heat 
inactivated before use. Inhibition of [125I] a-BGT 
binding was dependent on serum concentration for all the 
samples tested. As these assays were conducted at room 
temperature and 37#C, the results probably arose from 
increased energy-dependent receptor degradation, 
although direct blockade of the a-BGT binding site 
cannot be ruled out.
Theoretically, it is possible that antibodies could 
produce blockade of AChRs by binding at, or near to the 
active sites of the receptors, sterically hindering 
access to the sites, or by allosterically interfering 
with a-BGT binding (Figs. 44 and 45). It has been 
reported that only a small proportion of antibodies to
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Table 17. Inhibition of 112 51 ] a-BGT binding to various 
tissues by MLA.

















Fig. 44. Possible sites of attachment of anti- 
(AChR) antibody causing blockade of receptor.
a) Antibody attaches to acetylcholine binding site.
b) Antibody attaches near acetylcholine binding 
site and causes steric hindrance of 
acetylcholine and a-BGT binding.
c) Antibody does not directly interfere with the 
acetylcholine binding site, but alters the AChR 
molecule thus inhibiting acetylcholine and a-BGT 
binding.
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FIG. A-4 Possible sites of attachment of anti AChR antibody 




Fig# 45. Relative sizes of IgG, a-BGT, d-TC and 
acetylcholine with respect to the AChR.
Far right, AChR is depicted spanning the lipid 
bilayer.
IgG - white 
a-BGT - green 
d-TC - pink 
ACh - red
Molecular models constructed by V.B. Cockroft.
FIG. 45 Relative sizes of IgG, *-BGT, d-TC and acetylcholine 
with respect to the AChR.
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the AChR in myasthenic patients bindl directly to the a- 
BGT binding site itself (Dwyer et ad., 1979; Mittag et 
ad., 1981; Vincent and Newsom-Davis, 1979,1980,1982; 
Whiting et ad., 1983), although in other studies using 
chick muscle cells in culture (Fulpius., 1981) nearly 
half of the patients had some antibodies capable of 
binding to the site. However, the ability of antibodies 
to block binding of a-BGT may not necessarily parallel 
their ability to interfere with acetylcholine binding at 
the neuromuscular junction.
4.4. TE671 cells for the investigation of complement-
mediated lysis.
In view of the disadvantages (sporadic supply and 
ease of contamination) of human muscle cell cultures, 
TE671 cells were chosen as carriers of human muscle-type 
receptor (see Section 4.2.) for further investigations 
of complement-mediated cytotoxicity.
In the majority of cytotoxicity assays the target 
is prelabelled with radioisotope which is released upon 
lysis of the cell. However, enzyme release can provide a 
cheap and convenient alternative assay. Szekeres et ad. 
(1981), reported a method of determining cytotoxicity by 
measuring the alkaline phosphatase activity released 
from human embryonic fibroblast cells and Korzeniewski 
and Callewaert (1983) found that LDH is released in 
sufficient amounts in short term cytotoxicity assays, 
providing a sensitive and quantitative measure of
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natural cytotoxicity. As multiwell scanning
spectrophotometers can measure large numbers of samples 
with a high degree of precision, the possibility of 
using a colour reaction as a monitor of complement- 
mediated cytotoxicity towards TE671 cells was 
investigated. The assay was based on those previously 
described (Bergmeyer and Bernt, 1974; Mossman, 1983; 
Korzeniewski and Callewaert, 1983; Decker and Lohmann- 
Mathes, 1988), but employed the tetrazolium salt, p- 
iodonitrotetrazolium violet, as the substrate. Activity 
of LDH in the cellular supernatant, monitored by optical 
density at 492nm, indicates the proportion of lysed 
celIs.
Initial experiments tested the effects of normal 
and myasthenic serum samples, all of which had been 
heat-inactivated. All of the samples apparently caused 
release of LDH. The cytotoxicity was not enhanced by the 
addition of complement (Table 11 and Fig. 24) and 
correlation of anti-AChR antibody titre with 
cytotoxicity values was poor. In order to investigate 
this further, the cytotoxic effect of increasing 
concentrations of serum and GPC on the TE671 cells was 
studied. Variation was apparent between experiments 
(Fig. 25a-d) but there was still no difference between 
normal and myasthenic sera in the presence or absence of 
complement (Fig. 25e and f). The use of fresh myasthenic 
serum in one experiment showed marked cytotoxicity 
towards the cells but this was not repeatable in further 
experiments (Fig. 26) although it was observed that
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cytotoxicity, if noticeable, was present at lower added 
concentrations of serum. The serum concentration range 
was further reduced and variation in the lower added 
range was again marked. This effect was attributed to 
the difficulties encountered in adding and adequately 
mixing very small quantities of serum in the 96-well 
culture plates without perturbing the monolayer.
The effect of heat inactivation versus non-heat 
inactivation of fresh serum samples on complement- 
mediated lysis also revealed no significant difference 
in cytotoxicity (Fig. 27a-d).
Investigations of the presence of endogenous LDH in 
normal and myasthenic sera did show background levels 
but these were considered to be low enough (20-50% of 
total LDH releasable from Triton lysed TE671 cells) so 
that increases due to complement mediated lysis could be 
measured.
LDH exists as a number of isoenzymes; LDHl 
predominates in serum and LDH5 predominates in skeletal 
muscle (Table 18). In MG, cellular damage at the muscle 
end-plate may result in LDH5 release from skeletal 
muscle. If either or both of these isoenzymes in the 
serum samples could be inactivated specifically, the 
released LDH from TE671 cells could be more accurately 
measured.
LDH5 shows maximum activity at 42#C (Bergmeyer and 
Bernt, 1974). Temperatures above this result in 
denaturation. As the majority of serum samples were 
routinely heat-inactivated (56#C, lh) before use or
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Heart muscle LDHl heart muscle 
red blood cells 
kidney glomerular cells 
blood platelets 
eye lens
Skeletal muscle LDH 5 skeletal muscle 
liver
kidney tubule cells 
granulocytes 
malignant tumours
Smooth muscle LDH 3 smooth muscle
continuously contracting 
skeletal muscle
Taken from Bergmeyer and Bernt (1974)
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storage, the LDH activity still detectable in serum 
samples was thought to be attributable to LDHl. Further 
heat inactivation of these samples (60-75#C, lh) caused 
substantial, visible aggregation, rendering the samples 
useless for further assay.
The adsorption of serum samples onto two matrices, 
DEAE-Sephadex A-50 and Matrex Blue-gel A (Section 
2.11.4.3.) was investigated as a means of specific 
removal of LDHl (Bergmeyer and Bernt, 1974). In both 
cases serum LDH levels were reduced by about 50-65% 
(Figs. 30 and 31). However, both methods resulted in the 
concommittant reduction in anti-AChR antibody titre [10- 
20% loss with Sephadex A-50 and 30% loss with Blue-gel A 
(Table 12)]. Subsequent assays of lysis with Sephadex A- 
50 adsorbed serum samples, failed to demonstrate 
differences in lysis with myasthenic serum and GPC (Fig. 
32) .
From these results it was concluded that whilst 
levels of LDH in the serum could be reduced, the assay 
itself was not sensitive enough to monitor complement- 
mediated lysis of myasthenic serum towards the AChR on 
TE671 cells.
Further investigations of the cytotoxic effect of 
myasthenic serum on TE671 cells were carried out by 
using radiolabel. TE671 cells readily take up both L- 
[ME-3H] carnitine and [51Cr] (Figs. 33 and 34). However, 
TE671 cells are not contaminated by additional cell 
types in culture. The reason for choosing L-[Me-3H] 
carnitine in the myotoxicity studies is to
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differentiate lysis specifically from muscle cells, 
from that of any other cell types and so the cheaper 
[51Cr] label was chosen in these studies.
The quantitation of immune cytolysis based on the 
detection of released [51Cr] from lysed nucleated cells 
was introduced by Goodman (1961). This method has been 
useful and [51Cr] fulfills the expected criteria of a 
marker for labelling a single population of target 
cells:- It is non-toxic, the release of radiolabel from 
the target is even, the detection is relatively easy and 
sensitive and, what is most important, it does not 
change the morphology and characteristics of the target 
cells (Blomberg et al. (1986).
Uptake of [51Crl by TE671 cells was not saturable 
over the range studied (0-2yCi/well and 0-20yCi/wel1) 
but levels of radioactivity taken up were adequate. Loss 
of radioactivity from the cultures was approximately 
3%/hour, in agreement with the findings of Blomberg et 
aJL. (1986), who found also found that spontaneous 
release of [51Cr] from cells is relatively low.
Preliminary experiments tested the effects of 
increasing concentrations of heat-inactivated myasthenic 
and normal serum samples on [5*Cr]-labelled TE671 cells. 
Cytotoxicity increased with increasing serum 
concentration, a decrease in cytotoxicity at high 
concentrations of normal human serum (80-90%, Fig. 37) 
was due to loss of cells from the culture plate. The 
addition of complement in further assays revealed 
variation between samples. However, cytotoxicity was
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most marked at 20% serum.
Subsequent assays for cytotoxicity, employed 20% 
serum. For only one patient (MG2), was the combination 
of myasthenic serum and GPC found to be most effective 
at promoting lysis.
The specificity of the antibody-dependent 
complement-mediated cytotoxicity to TE671 cells was 
investigated by using an antiserum raised in rabbit 
against purified fetal calf AChR.
Using the same assay conditions as in the 
cytotoxicity of serum and GPC, rabbit anti-(fetal calf 
AChR) antiserum produced loss of [51Cr] from TE671 
cells, but only at the level of 15% lysis.
These results, with the experimental antisera 
suggest that "real” lysis with the serum was not being 
achieved, as levels for cytotoxicity were within the 
range defined as "control" by Childs et ad. (1984, 1985, 
1987). Whilst it was shown that TE671 cells could be 
lysed with water and the non-ionic detergent Triton X- 
100, the data presented suggest that TE671 cells are 
resistant to complement effects mediated by antibodies 
towards the AChR from either human or animal sources. 
Possible reasons for this lack of lysis could be:-
1)Low cell surface density of AChR on TE671 cells.
2 )Ineffective source of complement.
3)Difficulty in achieving lysis by a complement-
mediated mechanism of any nature.
It is known that TE671 cells have cell surface 





binding. However, the density of AChRs on TE671 cells is
reported to. be low (Sine, 1988). If this is true,
complement activation may be inhibited in the manner
described for fetal muscle cells in culture (Section
4.2.). Whether continuous repassaging of TE671 cells
affects AChR properties or a reduction in actual
numbers of binding sites is undocumented.
Ineffectiveness of the complement source was 
thought to be an unlikely reason, as the same 
complement, when coupled with myasthenic serum gave
demonstrable lysis of human muscle cells in culture 
(Section 4.2.).
An investigation of other specific antibodies
effecting complement-mediated lysis was not included in 
this study. This could, however, be studied using an 
alternative cell surface marker or protein as the 
antigenic target, or by preparing anti "TE671 cell
membrane" or anti "TE671 cell" antibodies, for use with 
a known complement source.
In the myotoxicity and cytotoxicity experiments 
carried out for this project it is probable that the 
antibodies responsible for the observed lysis were 
directed at the AChR on the human myotube cultures and 
TE671 cell membranes. The effects of a specific anti- 
AChR antibody could be investigated using monoclonal 
antibodies raised against the native receptor. However, 
in addition to antibodies directed at the AChR, patients 
with MG have circulating antibodies to various other 
skeletal muscle antigens, although these antibodies
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might not be directly involved in a JLytic response, they 
may represent a large proportion of the total serum 
antibody population and their presence should not be 
ignored.
4.5. Involvement of other antibodies in MG.
Anti-striational antibodies directed against 
cytoplasmic elements of the contractile apparatus have 
been documented in MG (Newsom-Davis and Vincent, 1982). 
The presence of these antibodies was demonstrated before 
the involvement of anti-AChR antibodies was suggested 
(Strauss et a_l. , 1960; Van der Gold et al_., 1963;
Beutner et ad., 1966). Anti-striational antibodies are 
mainly associated with thymoma (Oosterhuis et a^., 1976) 
but this is not specific for MG as 25% of patients with 
thymoma not associated with MG also have circulating 
anti-striational antibodies (Oosterhuis et ad., 1976; 
Limburg et ad., 1983). Further evidence for the 
involvement of non-"receptor" proteins as antigens in MG 
has been put forward. Evoli et ad. (1989) found anti- 
filamin antibodies in patients with MG, however, these 
tended to be associated with occular MG rather than the 
generalised disease.
Non-receptor muscle antibodies in MG have often 
been regarded as specific for components of contractile 
proteins. Aarli et ad. (1989) recently demonstrated 
binding of MG serum antibodies to the terminal cisterns 
of sarcoplasmic reticulum of striated muscle I bands.
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They further investigated the antigenicity of fractions 
of rat muscle horaogenate, finding that only fractions 
containing membrane proteins and not contractile 
proteins, showed a strong reaction with MG sera known to 
contain non-receptor antibodies (Aarli et ad., 1989). 
These data suggest that the antibody repertoire in MG is 
very extensive and that all parts of the muscle may 
serve as autoantigens although it is unknown as to 
whether they are all pathogenic.
Myasthenic sera may contain antibodies against 
other cell surface determinants which could affect 
receptor activity indirectly. Evidence for the presence 
of such antibodies comes from a study by Muller and 
Anderson (1984) demonstrating the presence of antibodies 
against cell surface antigens on human medulloblastoraa 
cells in the sera of patients with MG. That myasthenic 
sera contains antibodies against cells of neuronal 
origin suggests a more generalised neuroimmunological 
abnormality may exist in at least some patients.
In MG there is clearly a heterogeneous population 
of antibodies, not all of which are pathogenic. Disease 
state may be more closely related to sub-populations of 
anti-receptor antibodies or against particular 
determinants on the AChR.
4.6. Autoimmune response in MG.
The initiation of autoantibody production in MG 
remains terra incognita, although it undoubtedly does
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not involve immunisation with a dose of exogenous AChR 
in adjuvant. There is some evidence that autoimmune 
activity against AChR takes place within the thymus 
gland. Willcox et aJ. (1984) noted an increase in B-
cells capable of producing IgG, some of which were 
directed at AChR. They also noticed (Willcox et al .,
1984) that thymic lymphocytes from myasthenic patients 
cultured in vitro produced anti-AChR antibodies. These 
findings suggest that the thymus glands from at least 
some myasthenic patients contain the elements required 
for an immune response. Although the thymus is not a 
major producer of the patient's anti-AChR antibody, it
may well be an important site for the origin and
maintenance of the autoimmune esponse in MG.
The association of thymic abnormalities with MG and 
the presence of antibodies directed against other muscle 
components suggest that the initiating mechanism could 
involve more than the AChR per se. Lentz et ad. (1986) 
noticed that the rabies virus is capable of using the 
AChR as a tissue specific recognition site, Steffanson 
et ad. (1985) showed that various common pathogenic 
bacteria can cross react with monoclonal antibodies 
directed against the AChR. These data imply that an 
immune process triggered by a viral infection or 
bacterial infection may induce an autoimmune response 
against the AChR.
Irrespective of how the autoimmune response is 
initiated, the question of how the response is 
maintained has yet to be answered. Under normal
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circumstances, once initiated, an immune response tends 
to subside in the absence of antigen. Experimental 
administration of exogenous AChR initiates EAMG in 
animals (Patrick and Lindstrom, 1973; Heilbronn and 
Mattson, 1974) but maintenance of the autoimmune 
response requires repeated administration of AChRs 
(Drachman, 1987).
Various mechanisms have been proposed for 
imraunoregulation and its breakdown. No-one can give a 
satisfactory explanation and the process is more complex 
than at first sight. However, an alteration in 
immunoregulation seems likely for the autoimmune 
response in MG (Fig. 46).
The possibility that there may be a deficiency of 
suppressor cells specific for anti-AChR antibody has 
been proposed (Shapiro et ad, 1981; Richards et a_l., 
1986). Suppressor T-cells are thought to down-regulate 
the immune response. Asherson et ad. (1986) suggested 
that once AChR-specific suppressor cells are activated 
specifically, they secrete factors that non-specifically 
suppress the immune response. Drachman (1987), 
suggested that the occurence of antibodies against 
several antigens besides the AChR in some patients 
indicates that they may lack suppressor mechanisms for 
more than one antigen.
The production of autoantibodies is not limited to 
disease, but appears to be part of the normal B-cell 
repertoire. It is conceivable that the isotype of the 
antibody could be important in determining its capacity
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Fig. 46. Some possible interactions in an immune 
response to self.
Autoimmunity arises through bypass of the control 
of autoreactivity. The constraints on the stimulation 
of self reactive inducer/helper T-cells by autoantigen 
can be circumvented either through by-passing the 
inducer cell or by disturbance of the regulatory 
mechanisms.
Taken from Roitt, 1987.
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to cause disease. Most natural autoantibodies are of the 
IgM class, while disease autoantibodies tend to be IgG 
(Cohen and Cooke, 1986). Thus an immunoglobulin class 
switch may be critical in the disease process (Cohen and 
Cooke, 1986).
The relative proportions of the IgG isotypes within 
the anti-AChR antibody population are important. Lefvert 
and co-workers (Lefvert and Bergstrom, 1987; Lefvert et 
al., 1981) and Rodgaard et al. (1987) noted a prevalence 
of IgG3 in anti-AChR antibodies, whereas other groups 
reported low levels of IgG3 (Vincent and Newsom-Davis, 
1982; Whiting et ad, 1983) with a predominance of IgGl 
or IgG2 (Vincent and Bilku, 1982; Vincent and Newsom- 
Davis, 1982). The IgG isotypes vary in their ability to 
bind Clq and activate complement tightly (Burton et al.,
1985), IgGl and IgG3 being the most effective. However, 
storage of samples is important (Fulpius et a_l, 1981; 
Lefvert et ad., 1981) as the immunoglobulins are
susceptible to proteolytic degradation. The Fc region 
must remain intact to be functional in complement-
related lytic investigations.
C3 is the central component of the complement
pathway and measurement of its breakdown products 
reflects activation both the classical and alternate 
pathways. Most activated C3 reacts with water and is 
broken down to free C3d. C3d levels are thought to
reflect the degree of complement activation in vivo 
(Charlesworth et al., 1974) and in vitro (Perrin et ad., 
1975) because C3d has the longest half life of the C3
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breakdown products (Char lesworth et a^ l. , 1974).
Monitoring C3d for elevation of disease activity and 
complement activation dynamics has considerable 
advantages. In particular, determination of C3d has 
been considered to be a valuable parameter in evaluating 
disease activity in patients with the autoimmune 
disease, rheumatoid arthritis especially those with 
extra-joint manifestations (Nydegger et ad., 1977; 
Bedwell et a_l., 1986).
In a preliminary study to investigate an effect of 
C3d in MG and perhaps to correlate this with values 
obtained in the myotoxicity or cytotoxicity studies or 
with clinical state, use was made of a double-decker 
rocket immunoelectrophoresis technique developed by 
Brandslund et al. (1981) for investigating C3d activity 
in rheumatoid arthritis. With respect to reference 
preparations where C3 degradation was either prevented 
or spontaneous conversion of C3 in serum was allowed 
(37°C, 5 days), all of the myasthenic sera tested were 
positive and results did not correlate with titre (Fig. 
41). It has been documented that activation and 
degradation of complement factors are influenced in 
vitro by temperature, time and the coagulation process 
(Sinosich et ad., 1982). The EDTA samples used 
in this study had been stored, frozen (-80°C) for 
several months. This effect was noticed after the same 
samples (Fig. 41d) were re-assayed at Southmead 
Hospital, Bristol, U.K. and levels of C3d were found to 
be higher than for the previous assay (Fig. 41c). That
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all of the serum samples tested were positive was 
considered unusual (R. Czudek, personal communication) 
but could be ascribed to storage or collection of the 
samples used.
It is likely that both complement-mediated attack 
and AChR modulation contribute to the AChR deficiency at 
the MG end plate. Lysis of the post synaptic membrane 
not only causes immediate loss of AChR, but also reduces 
the membrane surface available for insertion of new 
AChR. This in turn enhances the subsequent depletion of 
AChR by both modulation and complement. Modulation on 
the other hand, by decreasing the density of AChR and 
hence the antibody bound to AChR, may decrease 
complement fixation and thus help the post synaptic 
membrane escape destruction from subsequent membrane 
attack.
Conclusions and future prospects.
Previous investigations in this laboratory have 
successfully demonstrated complement-mediated lysis of 
myasthenic serum towards rat muscle cells in culture 
(Childs et ad., 1984,1985,1987). This study investigated 
the same effect on human tissue and cell culture 
systems, proposing that they would serve as a better 
model for a human disease.
Human fetal muscle cells in culture showed 
myotoxicity but only at high levels of added serum and 
complement. Such an effect may be related to immaturity
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of the cells in culture. Lysis of TE671 cells was 
demonstrated using either distilled water or Triton X- 
100 but a specific lytic effect of serum and complement 
was not apparent. These data suggest that TE671 cells 
have very resistant cell membranes.
The nature of the antibodies producing lytic 
activity and the role of complement require further 
investigation.
A more detailed examination of the IgG isotypes 
within patients, coupled with complement activation 
monitored via measurement of C3d could provide greater 
insight into the involvement of complement in MG.
TE671 cells are a good source of AChR but results 
from this study suggest that they are not a suitable 
cell type for the investigation of complement-mediated 
lysis.
It has very recently been suggested (Larsson and 
Sjoquist, 1989) that an assay measuring cell lysis is 
probably not the most appropriate method for use in 
patients with suspected autoimmune diseases, since it is 
mainly deficiencies of the classical complement pathway 
components that are associated with these diseases. 
This, however, does not dismiss the use of TE671 cells 
to benefit further study of MG and aspects of the AChR.
MG is the best characterised autoimmune disease of 
the nervous system. Several important aspects of MG are 
clearly known. It is clear that neuromuscular 
transmission is impaired as a result of several antibody 
mediated mechanisms in response to muscle AChRs. Assay
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of the antibodies produced can improve diagnosis. 
Advances in the study of AChRs and immunology have 
permitted greater definition of the antigenic structure 
of the AChR and the cellular interactions involved in 
the production of antibodies.
If the pace of new development, with respect to 
molecular biology and immunology continues, a specific 
cure rather than palliative treatments may provide MG 
patients with a more acceptable quality of life.
APPENDIX
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1 3.1.4. 49 55
2 vv 30 47
3 if 32 60
4 if 33 nd
5 ft 35 nd
Table 20. Sera used in the cytotoxicity study.
Serum Result section % Cytotoxicity % Myotoxicity
No. number (This study) (Childs, 1985)
LDH [5iCr]
1 3.2.4.2. 3.2.6.4. _ 55
3.2.4.3. 3. 2 .6 • 5 . -
3.2.4.4. 3 .2 . 6 .7 . -
3.2.5.1. -
2 3.2.4.3. 3 . 2 .6 .7 . - 47




3 . 2 • 5 • 6 . -
6 3.2.4.3. 3 . 2 . 6 . 7 . - nd
3.2.5.1. -
7 3.2.4.3. - nd
8 3.2.4.4. - nd
9 3.2.4.4. - nd
3 • 2 • 4 • 6 . -
10 3.2.4.5. - nd
11 3.2.4.5. - nd
3 . 2 . 5 .1. - nd
12 3.2.4.7. 3.2.6.7. - nd
3.2.5.1. -
3.2.5.2. -
3 .2 .5 .6 . -
3.2.5.7. -
13 3.2.4.7. - nd
3.2.5.1. -
3 .2 • 5 . 2 . -
3 .2 . 5 . 6 . -
14 3.2.6.7. nd
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